Oral Presentations

AASLD/ASGE Endoscopy Course

Friday, November 1

7:55 AM - 3:00 PM Room 146A

Endoscopy in Patients with Hepatobiliary Disorders: Evolving Concepts, Technologies and Techniques


Barham K. Abu Dayyeh, MD

6.5 CME Credits

The overall goal of this activity is to educate the target audience in state-of-the-art best practices pertaining to diagnostic and therapeutic endoscopy in patients with hepatobiliary disease. This should result in a significant improvement in their understanding of the relative benefits and risks of these modalities, in optimizing patient selection for different endoscopic interventions and in the performance of these endoscopic interventions.

Learning Objectives:

  • Advise on the state of the literature and “best practice” consensus recommendations regarding these commonly encountered issues prior to endoscopy
  • Identify the most up-to-date endoscopic and non-endoscopic management strategies, along with their associated risks and outcomes
  • Discuss the management of gastric antral vascular ectasia (GAVE), specifically the relative merits of difference ablative endoscopic therapies such as radiofrequency ablation, Argon Plasma coagulation and cryotherapy
  • Describe evolving technologies and techniques in the management of both benign and malignant hepatobiliary disease

7:55 - 8:00 AM Welcome

Subhas Banerjee, MD

Session I: General Topics

8:00 - 8:20 AM Endoscopy in the Cirrhotic Patient: Navigating the Hazards of Coagulopathy, Encephalopathy, Ascites and Immune Suppression

Shai Friedland, MD

8:20 - 8:40 AM Endoscopy And Endotherapy In The Pre-Transplant Liver Patient: What Do I Do For My Patients With Barrett's Esophagus, Colonic Polyps And Choledocholithiasis?

Douglas G. Adler, MD

8:40 - 9:00 AM Sedation and Anesthesia for Endoscopy in the Cirrhotic Patient: A Gastroenterologist's Perspective

John Vargo, MD

9:00 - 9:10 AM Questions for the Panel

9:10 - 9:30 AM Coffee Break

Session II: Portal Hypertension

9:30 - 9:50 AM Esophageal Varices: Screening, Primary/Secondary Prophylaxis and Management of Acute Bleeding

Guadalupe Garcia-Tsao, MD

9:50 - 10:10 AM Gastric Varices: Current Practice and New Developments

Janak Shah, MD

10:10 - 10:30 AM Portal Hypertensive Gastropathy and GAVE: Current Practice And New Developments

Louis M. Wong Kee Song, MD

10:30 - 10:40 AM Questions for the Panel

10:40 - 11:10 AM Break

Session III: Endoscopy for Diagnosis and Therapy In The Bile Duct

11:10 -11:30 AM PSC: Diagnosis, Surveillance, and Management of Dominant Strictures

Todd H. Baron, MD

11:30 - 11:50 AM Cholangiocarcinoma: Role of Endoscopy in Diagnosis And Management

David G. Forcione, MD

11:50 AM - 12:10 PM Endoscopic Management of Post-Liver Transplant Biliary Complications

Subhas Banerjee, MD

12:10 - 12:20 PM Questions for the Panel

12:20 -1:20 PM Lunch

Session IV: Emerging Technology and Techniques in Hepatobiliary Disorders

1:20 - 1:40 PM Choledochoscopy, Narrow Band Imaging, and Con-Focal Endomicroscopy for Biliary Disease

Raj J. Shah, MD

1:40 - 2:00 PM Endoscopic Ultrasound Guided Hemostasis and Biliary Access

Michael J. Levy, MD

2:00 - 2:20 PM When Endotherapy Fails: Calling In Your Friendly Neighborhood Interventional Radiologist

Daniel Y. Sze, MD, PhD

2:20 - 2:40 PM Endoscopic Therapy for Obesity and Non-Alcoholic Fatty Liver Disease: Are We There Yet?

Barham K. Abu Dayyeh, MD

2:40 - 2:55 PM Questions for the Panel

2:55 - 3:00 PM Closing Address

Barham K. Abu Dayyeh, MD

AASLD/IASL Symposium

Friday, November 1

8:00 AM -12:30 PM Room 145

AASLD/IASL Symposium


K. Rajender Reddy, MD

4 CME Credits

Session I Learning Objectives:

  • Understand hypersplenism in patients with cirrhosis
  • Manage patients with disease of the hepatic and portal veins
  • Describe complications of portal hypertension in schistosomiasis and idiopathic portal hypertension

Session II Learning Objectives:

  • Identify the differences in NAFLD and NASH in East vs. West
  • Explain current approaches to the treatment of NASH and NAFLD

Session I: Portal Hypertension: Global Perspective

8:00 - 8:05 AM Introduction

Thomas D. Boyer, MD

8:05 - 8:25 AM Portal Hypertension in Schistosomiasis: Management

Alberto Q. Farias, MD, PhD

8:25 - 8:45 AM Huge Spleens and Hypersplenism: Observe, Embolize or Remove

Thomas D. Boyer, MD

8:45 - 9:05 AM Management of Budd-Chiari Syndrome

Juan Carlos Garcia-Pagan, MD

9:05 - 9:25 AM Management of Portal Vein

Thrombosis: With and Without Cirrhosis

Dominique Valla, MD

9:25 - 9:45 AM Idiopathic Portal Hypertension: Diagnosis and Management

Shiv K. Sarin, MD

9:45 - 10:05 AM Panel Discussion and Questions

10:05 -10:25 AM Break

Session II: NAFLD/NASH: Global Perspective

10:25 - 10:30 AM Introduction

K. Rajender Reddy, MD

10:30 - 10:50 AM Global Epidemiology of NAFLD/NASH

Jeanne M. Clark, MD

10:50 -11:10 AM Pathogenesis of NASH - Geographical Differences

Jian-Gao Fan, MD,PhD

11:10 - 11:30 AM Gender, Racial and Ethnic Differences in NAFLD/NASH

Elizabeth E. Powell, MD

11:30 -11:50 AM NAFLD/NASH Presentation in the East vs. West

Deepak N. Amarapurkar, MD

11:50 AM -12:10 PM Therapy of NAFLD/NASH

Arun J. Sanyal, MD

12:10 - 12:30 PM Panel Discussion and Questions

AASLD/ILTS Transplant Course

Friday, November 1

8:00 AM - 3:30 PM Room 146BC

Liver Transplantation - First Quarter, Second Decade


John O'Grady

7.5 CME Credits / 6 Contact Hours

The overall goals of the course are to enhance understanding of up-to-date integrated care of the graft and patient during the first three months and to determine if management strategies should change with extended survival.

The course will initially take a focused view of the first three months after liver transplantation which remains the time period of highest risk to graft and patient. This section will deal with:

  • The critical definition of the role of intensive care after liver transplantation
  • The management of specific complications subject to evolving attitudes to management
  • The re-evaluation of diagnostic paradigms for common but non-specific patterns of graft dysfunction

The second part of the course will address the issue of survival into the second decade after transplantations and beyond. This is in response to the rapidly increasing number of patients entering this phase and the lack of attention this had received in educational symposia. This sections will deal with:

  • The expectations for graft survival independent of the threat of recurrent diseases
  • The ongoing relevance of recurrent disease
  • The challenges of adolescence
  • Immunosuppression strategies and tolerance
  • Surveillance and follow-up programs

Learning Objectives:

  • Define the role and cost-effectiveness of intensive care utilization
  • Critically evaluate the evidence to support the management of common early complications including acute cellular rejection and hepatic artery thrombosis
  • Define effective diagnostic pathways for graft dysfunction
  • Determine what could or should change in patient management beyond the first 10 years

Session I: First Quarter


8:00 - 8:10 AM Introduction and Why the First Quarter?

John R. Lake, MD

8:10 - 8:30 AM Justification for Routine Intensive Care after Liver Transplantation

Michael A. Ramsay, MD

8:30 - 8:50 AM Early Graft Dysfunction: Causes, Recognition and Management

Marc Deschenes, MD

8:50 - 9:10 AM Small-for-Size Syndrome: Recognition and Management

Chung-Mau Lo, MD

9:10 - 9:30 AM How Relevant is Acute Cellular Rejection?

Michael R. Charlton, MD

9:30 - 9:50 AM Hepatic Artery Thrombosis: Conservative Management or Retransplantation?

Nigel Heaton, MB, FRCS

9:50 - 10:10 AM Discussion

10:10 -10:30 AM Break

Session II: Quarter 1-Investigation of Graft Dysfunction


10:30 - 10:50 AM Systematic Investigation of Elevated Transaminases during the Third Posttransplant Month

Michael P. Curry, MD

10:50 - 11:10 AM Systematic Investigation of Elevated Cholestatic Enzymes during the Third Post-transplant Month

Andrew L. Mason, MBBS, MRCPI

11:10 -11:25 AM Specific Contribution of the Histopathologist

Stefan G. Hubscher, MD

11:25 - 11:40 AM Specific Contribution of the Advanced Endoscopist

Mustafa A. Arain, MD

11:40 AM - Noon Discussion

Noon - 1:00 PM Lunch

Session III: Second Decade


1:00 - 1:05 PM Why the Second Decade?

John G. O'Grady, MD

1:05 - 1:20 PM Will Retransplantation be the Norm for Pediatric Recipients with Ambitions for Grand-parenthood?

Deirdre A. Kelly, MD

1:20 -1:40 PM Adolescence - Challenges and Responses

Sue V. McDiarmid, MD

1:40 - 1:55 PM Long Term Quality of life in Transplant Recipients

Patrizia Burra, MD, PhD

1:55 - 2:15 PM Tolerance Profiles and Immunosuppression

Alberto Sanchez-Fueyo, MD

2:15 - 2:25 PM Is Disease Recurrence Still Relevant to Graft Survival?

James F. Trotter, MD

2:25 - 2:45 PM Extrahepatic Implications of the Metabolic Syndrome

Kymberly D. Watt, MD

2:45 - 3:05 PM Malignant Disease - Risk and Surveillance Strategies

Geoffrey W. McCaughan, MD, PhD

3:05 - 3:30 PM Discussion

AASLD/NASPGHAN Pediatric Symposium

Friday, November 1

Noon - 3:00 PM Room 150A

New Insights and Controversies in Liver-based Metabolic Diseases


Simon Horslen, MD

3 CME Credits

The purpose of the program is to review the advances made in the last 10-years within the field of metabolic liver diseases. This program will also offer the opportunity to review the pathophysiology of liver based metabolic disorders while gaining insights into the latest treatments available for management of these disorders. It will also specifically address candidacy for treatment and counsel. This will be the first comprehensive program at AASLD in nearly 10 years to address salient topics in cirrhotic and non-cirrhotic liver based metabolic disorders, including treatment, as well as advantages and disadvantages of treatment. This program will include national and international experts in the fields of metabolic liver diseases from multiple disciplines (pediatrics, internal medicine). Pediatric and Adult hematologists need a stronger fund of knowledge in metabolic liver diseases and increased competence in applying specific therapies to children and adults with metabolic diseases. Learners from this program will be able to utilize the most up to date clinical recommendations and guidelines within their practice while also renewing their understanding of the science and clinical consequences behind these diseases.

Learning Objectives:

  • Apply knowledge of the most current treatment options in different clinical settings
  • Recognize hepatic presentation of uncommon metabolic diseases and discuss the management with patients and families

Session I

Noon - 12:05 PM Introduction

12:05 - 12:25 PM Atypical Fatty Liver Disease: Genetic and Metabolic Contribution of Acid Lipase Deficiency

Pramod Mistry, MD, PhD

12:25 -12:45 PM Hemochromatosis and Wilson' Disease: Single Genes, Complex Diseases

Kris V. Kowdley, MD

How to get children with non-cirrhotic metabolic disease transplanted at the right time — too late to say too early?

12:45 -12:55 PM The Biochemical Geneticist's Perspective

Marshall Summar, MD

12:55 - 1:05 PM The Transplant Perspective

John C. Magee, MD

1:05 - 1:25 PM Panel Discussion

1:25 - 1:45 PM Break

Session II

1:45 - 2:05 PM Pros/Cons of Hepatocyte Transplantation for Treatment of Liver- based Metabolic Disease

Ira J. Fox, MD

2:05 - 2:25 PM Alpha 1 Antitrypsin Deficiency: Mechanism of Hepatocellular Injury and Novel Interventions

David H. Perlmutter, MD

2:25 - 2:45 PM Mitochondrial Cytopathies: Hepatic Phenotypes, Diagnosis, Prognosis and Management

Patrick J. McKiernan, BSc, FRCP

2:45 - 3:00 PM Discussion

Career Development Workshop

Friday, November 1

Noon - 3:30 PM Room 152A

Career Development Workshop

COURSE DIRECTORS: Richard K. Sterling, MD, MSc

Ayman A. Koteish, MD

This workshop is designed to assist clinical and research trainees and junior faculty pursuing careers in academic hepatology. In addition, participants will have the opportunity to network and meet leaders in the Hepatology field.

Learning Objectives:

  • Discuss the goals of the Hepatology Fellowship (the pilot and the fourth year tracks)
  • Describe the essential elements that define academic success
  • Explain the development of basic and clinical research projects and options for obtaining funding
  • Identify the current needs and future trends in academic Hepatology
  • Apply the dynamics of the mentor-mentee relationship and advance academically as a junior faculty/advanced fellow/postdoctoral fellow

Noon - 12:05 PM Introduction

12:05 - 12:25 PM Fourth Year / Pilot Transplant Hepatology Fellowship Tracks

Oren K. Fix, MD, MSc

12:25 -12:45 PM Grant Writing (K23, K08, R03, R21, R01)

Arun J. Sanyal, MD

12:45 - 1:05 PM Tips for Success in Basic and Clinical Research

Gyongyi Szabo, MD, PhD

1:05 - 1:25 PM NIH Career Development Awards

Judith Podskalny, PhD

1:25 - 1:40 PM Panel Discussion

1:40 - 2:00 PM Break

2:00 - 2:20 PM Negotiating Your First Contract

Bruce A. Luxon, MD, PhD

2:20 - 2:40 PM Academic Advancement

Adrian M. Di Bisceglie, MD

2:40 - 3:00 PM Understanding Clinical Epidemiology and Biostatistics

W. Ray Kim, MD

3:00 - 3:20 PM Making the Most of the Mentee-Mentor Relationship

Anna Mae Diehl, MD

3:20 - 3:30 PM Panel Discussion

Competency Training Workshop

Friday, November 1

12:30 - 3:00 PM Room 152B

Competency Training Workshop


K. Gautham Reddy, MD

This workshop is designed to assist Transplant Hepatology Program Directors, Program Coordinators, clinical faculty, and trainees in Transplant Hepatology, Gastroenterology and Internal Medicine in understanding the changes occurring in Transplant Hepatology training and assessment. Attendees will develop a better understanding of competency-based medical education specifically learned from the experience of the GI/Transplant Hepatology pilot training program. They will be able to better understand the new Transplant Hepatology milestones and their use in assessing and evaluating trainees and reporting to ACGME. Attendees will be updated on the progress of the Next Accreditation System (NAS) and gain a better understanding of its impact on Transplant Hepatology training and assessment beginning in July 2014, including a focus on the responsibilities of the Clinical Competency Committee and the need for faculty development in these areas.

Learning Objectives:

  • Describe the experience, progress and future developments of the GI/Transplant Hepatology pilot training program
  • Identify the knowledge of the Transplant Hepatology milestones and how to apply them in the assessment and evaluation of trainees
  • Describe the composition and role of the Clinical Competency Committee
  • Prepare for the Next Accreditation System

12:30 - 12:40 PM Introduction

Bruce A. Luxon, MD, PhD

12:40 - 1:00 PM The Next Accreditation System: Compliance for Transplant Hepatology Fellowships

K. Gautham Reddy, MD

1:00 -1:20 PM Update on the GI/Transplant Hepatology Pilot Training Pathway

Oren K. Fix, MD, MSc

1:20 - 1:40 PM Results of the Pilot Perceptions Survey and Perspectives from a Gastroenterology Fellow

Dina Halegoua-De Marzio, MD

1:40 - 1:50 PM Discussion

1:50 - 2:05 PM Break

2:05 - 2:25 PM The Transplant Hepatology Training Landscape of the Future

John R. Lake, MD

2:25 - 3:00 PM Panel Discussion and Q & A

Steven K. Herrine, MD, K. Gautham Reddy, MD, Oren K. Fix, MD, MSc and Andrew Keaveny, MD

3:00 - 3:00 PM Panel Discussion and Q & A

Andrew Keaveny, MD

AASLD Postgraduate Course

Friday, November 1

3:30 - 7:30 PM Hall E/General Session

New Treatments in Liver Disease A New Era of Diagnostics, Therapeutics and Intervention in Hepatology

COURSE DIRECTORS: Adrian M. Di Bisceglie, MD

Paul Martin, MD

12 CME Credits / 11.75 Contact Hours

The complexity and volume of current advances in the management of liver disease make it increasingly difficult for health care providers to apply this overwhelming amount of information to their practice. This course provides the learner with a comprehensive overview of the state-of-the-art advances in the management of chronic liver diseases based on the latest in both basic and clinical research. A thorough tour through the current treatment landscape is crucial to both health care providers and patients who can benefit from this expansion of therapeutic options.

Learning Objectives:

  • Become familiar with new therapies for patients
  • Become aware of new techniques available for diagnosis
  • Develop an appreciation of prospects for future therapies that may become available for patients

3:30 - 3:35 PM Introductory Remarks

Adrian M. Di Bisceglie, MD

Session I: Diagnosis of Liver Disease

MODERATORS: Zachary D. Goodman, MD, PhD

Nezam H. Afdhal, MD

3:35 - 3:55 PM Genetic Testing has Arrived: SNPs, Microarrays and Other Techniques

Andrew J. Muir, MD

3:55 - 4:15 PM Hepatic Pathology: New Diagnostic Tools

Elizabeth M. Brunt, MD

4:15 - 4:35 PM Current Status of Non-invasive Alternatives to Liver Biopsy: Do we still need liver biopsy to assess hepatic fibrosis?

Robert J. Fontana, MD

4:35 - 4:55 PM Hepatic Imaging — Use of New Contrast Agents

Jeffrey J. Brown, MD

4:55 - 5:15 PM New Biomarkers for Hepatocellular Carcinoma

Lewis R. Roberts, MD, PhD

5:15 - 5:35 PM Break

Session II: Old Diseases, New Treatments

MODERATORS: Jayant A. Talwalkar, MD

Marion G. Peters, MD

5:35 - 5:55 PM Autoimmune Liver Disease

Heiner Wedemeyer, MD

5:55 - 6:15 PM Controversies in Management of PSC

Cynthia Levy, MD

6:15 - 6:35 PM Pediatric Liver Disease in Adults

Deirdre A. Kelly, FRCPCH, FRCP, FRCPI, MD

Clinical Conundrums in Diagnosis

MODERATOR: Adrian M. Di Bisceglie, MD

6:35 - 6:47 PM Cirrhotic patient with high AFP but no mass

Gary L. Davis, MD

6:47 - 6:59 PM Iron Overload, wild-type HFEgene

Bruce R. Bacon, MD

6:59 - 7:11 PM Patient with apparent drug-induced liver injury, but uncertain drug culprit

William M. Lee, MD

7:11 - 7:30 PM Panel discussion on conundrums in diagnosis

Saturday, November 2

8:00 AM - 5:00 PM Hall E/General Session

New Treatments in Liver Disease A New Era of Diagnostics, Therapeutics and Intervention in Hepatology

Session III: Treatment of Viral Hepatitis


Michael W. Fried, MD

8:00 - 8:20 AM Management of Chronic Hepatitis B: Beyond the Guidelines

Tram T. Tran, MD

8:20 - 8:40 AM Current Status and Benefits of Therapy for Chronic Hepatitis C

Nancy Reau, MD

8:40 - 9:00 AM The Next Phase of Therapy for Hepatitis C

Ira M. Jacobson, MD

9:00 - 9:20 AM Difficult Treatment Decisions in Hepatitis C

Hugo E. Vargas, MD

9:20 - 9:40 AM Hepatitis E, Epidemiology, Diagnosis and Management

Timothy J. Davern, MD

9:40 -10:00 AM Break

Session IV: Fatty Liver Disease

MODERATORS: Florence Wong, MD

Mary E. Rinella, MD

10:00 - 10:20 AM Disease Associations with NAFLD

Kenneth Cusi, MD

10:20 - 10:40 AM Controversies in the Management of NAFLD

Mary E. Rinella, MD

10:40 - 11:00 AM Controversies in the Management of Alcoholic Hepatitis

Timothy R. Morgan, MD

Session V: “Preventive Maintenance” in Patients with Cirrhosis

MODERATORS: Guadalupe Garcia-Tsao, MD

Kevin D. Mullen, MD

11:00 - 11:20 AM Screening for Varices and Prophylaxis of Variceal Bleeding

Samuel S. Lee, MD

11:20 - 11:40 AM Cirrhosis in Women

J. Eileen Hay, MD

11:40 AM - Noon Nutrition in Cirrhosis

Arthur J. McCullough, MD

Noon - 12:15 PM Break

12:15 - 1:15 PM Meet-the-Professor Luncheons

Session VI: Management of Complications of Cirrhosis and Liver Transplantation

MODERATORS: Michael R. Lucey, MD

Lawrence S. Friedman, MD

1:15 - 1:35 PM Hepatorenal Syndrome and Hyponatremia

Guadalupe Garcia-Tsao, MD

1:35 - 1:55 PM Coagulation Disorders and Portal Vein Thrombosis

Stephen H. Caldwell, MD

1:55 - 2:15 PM Gallbladder and Biliary Disease in Cirrhosis

Robert H. Hawes, MD

2:15 - 2:35 PM Expanding the Spectrum of Hepatic Encephalopathy

Jasmohan S. Bajaj, MD

2:35 - 2:55 PM Enhancing Long-term Survival after Liver Transplantation

Michael R. Charlton, MD

2:55 - 3:15 PM Current and Future Treatment Options for Hepatocellular Carcinoma

Laura M. Kulik, MD

3:15 - 3:35 PM Break

Conundrums in Management of Cirrhotic Patients

3:35 - 3:47 PM Cirrhotic patient with persistent non-variceal Gl bleeding

Kimberly Ann Brown, MD

3:47 - 3:59 PM Patients with recurrent encephalopathy but low MELD

Jeffrey S. Crippin, MD

3:59 - 4:11 PM Refractory hepatic hydrothorax

Tse-Ling Fong, MD

4:11 - 4:35 PM Panel discussion on conundrums in treatment

4:35 - 4:55 PM Future Horizons in Treatment of Liver Disease

Adrian Reuben, MBBS, FRCP, FACG

4:55 - 5:00 PM Concluding Remarks

Paul Martin, MD

SIG Program

Saturday, November 2

9:00 AM - Noon Room 146A

Surviving and Thriving - A Value Based Approach for Multidisciplinary Liver Programs

Sponsored by the Liver Transplantation and Surgery SIG


David C. Mulligan, MD

This session is to set the stage for insight into how high performing and high quality programs in public and private institutions have addressed the challenges of limited resources. These programs have met the challenge to maintain or exceed expectations with ever more tightly controlled accountability in performance and cost, utilizing quality improvement and other processes as effective tools to inform how best to accomplish this feat.

Learning Objectives:

  • Understand the language of value based multidisciplinary care
  • Identify the value of and integrate quality improvement into day to day clinical practice
  • Explain how to use quality to leverage the necessary resources to support and develop your program
  • Gain insights to the transition of integrated multidisciplinary care

9:00 - 9:05 AM Introduction

Session I: Successes and Challenges in Sustaining Excellence in the Public University Setting

9:05 - 9:25 AM Perspectives From A Surgical Program Director-Public Sector

Prabhakar Baliga, MD

9:25 - 9:30 AM Discussion

9:30 - 9:50 AM Perspectives From A Medical Program Director

John R. Lake, MD

9:50 - 9:55 AM Discussion

9:55 - 10:15 AM Surviving and Thriving with Value and Excellence From an Administrative Perspective

Jennifer Milton, RN, MSN

10:15 - 10:20 AM Discussion

10:20 -10:30 AM Break

Session II: Successes and Challenges in Sustaining Excellence in Private Health Care Systems

10:30 - 10:50 AM Perspectives From A Surgical Program Director

William C. Chapman, MD

10:50 - 10:55 AM Discussion

10:55 - 11:15 AM Perspectives From A Medical Program Director-Private Sector

James F. Trotter, MD

11:15 - 11:20 AM Discussion

11:20 - 11:40 AM Surviving and Thriving with Value and Excellence

Karen Hess, RN, MS, MBA, ACNP

11:40 - 11:45 AM Discussion

11:45 AM - Noon Panel Discussion

Meet-the-Professor Luncheon

Saturday, November 2

12:15 -1:15 PM Refer to your luncheon ticket for meeting room location.

MTP-1 Use of Statins in Patients with Liver Disease

Curtis K. Argo, MD and Naga P. Chalasani, MD

MTP-2 Safe Prescribing in Liver Disease

James H. Lewis, MD and Timothy J. Davern, MD

MTP-3 Herbs and Natural Remedies in Patients with Liver Disease

Victor J. Navarro, MD and Leonard B. Seeff, MD

MTP-4 HCV: Treat Now or Wait

Paul J. Pockros, MD and Christoph Sarrazin, MD

MTP-5 HCV: Side Effects of New Antiviral Agents

John F. Reinus, M.D. and Reem H. Ghalib, MD

MTP-6 Hepatitis C Management in the Liver Transplant Candidate

Catherine T. Frenette, MD and Marina Berenguer, MD

MTP-7 The Hepatitis C Drug Pipeline

Douglas T. Dieterich, MD and Raymond T. Chung, MD

MTP-8 Optimal Management of Hepatic Encephalopathy

Norman Gitlin, MD and Kevin D. Mullen, MD

MTP-9 Viral Hepatitis and HIV Infection

Norbert Brau, MD and Maribel Rodriguez-Torres, MD

MTP-10 Viral Hepatitis in Patients Undergoing Heart, Kidney and Bone Marrow Transplants

Michael P. Curry, MD and Maya Gambarin-Gelwan, MD

MTP-11 HCC: How to Screen

Roniel Cabrera, MD and Jose Franco, MD

MTP-12 NAFLD: Who to Biopsy

Neeral L. Shah, MD and Nizar N. Zein, MD

MTP-13 OLT: Improving Long-term Outcomes

Francisco A. Durazo, MD and Jacqueline G. O'Leary, MD

MTP-14 Endoscopy Issues in Patients with End-stage Liver Disease

Vijay Shah, MD and Bruce A. Luxon, MD, PhD

MTP-15 Alcoholic Hepatitis: What Should I do?

Philippe Mathurin, MD, PhD and Timothy R. Morgan, MD

Poster Session I

Saturday, November 2

2: 00 - 7: 30 PM

Hall E

Refer to page 92A for Poster Presentations

Exhibit Hall Opening and Reception

Saturday, November 2

5: 00 - 7: 30 PM

Hall D

Transplant Surgery Workshop

Saturday, November 2

3:30 - 7:00 PM Room 146A

Management of Rare Liver Tumors


Kenneth D. Chavin, MD, PhD

3.5 CME Credits

The program will provide the audience with an evidence based review of the current diagnostic and treatment strategies for less commonly encountered liver tumors.

Learning Objectives:

  • Identify the steps in diagonsis and the various treatment strategies for poly-cystic liver disease, hepatic adenomas and metastatic neuroendocrine cancers

3:30 - 3:35 PM Introduction and Aims of the Program

Session I: Polycystic Liver Disease

3:35 - 3:50 PM Liver Resection, Transplantation and Fenestration For Polycystic Liver Disease

David M. Nagorney, MD

Session II: Adenoma

3:50 - 4:10 PM Imaging Characteristics of Adenomas

BachirTaouli, MD

4:10 - 4:30 PM How Molecular and Immunohistochemical Analyses Can Help Us Guide Therapy For Hepatic Adenomas and FNH

Jessica Zucman-Rossi, MD, PhD

4:30 - 4:50 PM Resection, Transplantation and Local Regional Therapies For Adenomas

Jacques Belghiti, MD

4:50 - 5:10 PM Break

Session III: Neuroendocrine Tumors

5:10 - 5:30 PM Imaging Characteristics of Neuroendocrine Tumors

Bachir Taouli, MD

5:30 - 5:50 PM Current NANETS and ENETS Guidelines for Management Of Neuroendocrine Tumors

Diane Reidy, MD

5:50 - 6:10 PM Liver Transplantation for Neuroendocrine Tumors

Vincenzo Mazzaferro, MD

6:10 - 6:30 PM Liver Resection and Local Regional

Therapies for Neuroendocrine Tumors

Timothy M. Pawlik, MD, PhD

6:30 - 6:40 PM Debate: Patients with Neuroendocrine Tumors Will Do Well No Matter What We Do - So Why Treat Them?

Vincenzo Mazzaferro, MD

6:40 - 6:50 PM Debate: Patients with Neuroendocrine Tumor Will Do Better With Aggressive Treatment

Timothy M. Pawlik, MD, PhD

6:50 - 7:00 PM Closing Remarks


Saturday, November 2

5:15 - 6:15 PM

Hall E - General Session Room

J. Gregory Fiz, MD, presiding

Early Morning Workshops

Sunday, November 3

6:45 - 7:45 AM Refer to your luncheon ticket for meeting room location.

Sunday Basic Early Morning Workshops

Goals and Objectives:

  • Bring together investigators in a specific area of research to discuss their ongoing work.
  • Focus of discussions is on new work and not a review of previous studies.
  • Allow ample time for questions from the audience.

EMW-1 Artificial Liver Support Systems

Jayanta Roy-Chowdhury, MD and Vicente Arroyo,

EMW-2 HCV Replication

Andrew H. Talal, MD and Raymond T. Chung, MD

EMW-3 Triggers of Fibrosis in NASH

Ariel E. Feldstein, MD and Detlef Schuppan, MD, PhD

EMW-4 Cholangiocyte Pathobiology

Gianfranco Alpini, PhD and Marco Marzioni, MD

EMW-5 Microbiome and the Liver

Bernd Schnabl, MD and David Brenner, MD

EMW-6 Animal Models of NAFLD

Rohit Kohli, MD and Michael R. Charlton, MD

Sunday Clinical Early Morning Workshops

Goals and Objectives:

  • Discuss difficult management issues utilizing acknowledged experts in the area.
  • Provide an overview of the current state-of-the-art in each area.
  • Allow ample time for questions from the audience.

EMW-7 Imaging of Liver Tumors

Claude B. Sirlin, MD and Laura M. Kulik, MD

EMW-8 Liver Transplantation for Hepatitis C

Xavier Forns, MD and Norah Terrault, MD

EMW-9 New Anti-Tumor Agents in Development for HCC

Jorge A. Marrero, MD and Josep M. Llovet, MD

EMW-10 Quality Improvement in Management of Patients with Liver Disease

Fasiha Kanwal, MD and Michael Volk, MD

EMW-11 Hepatitis B: Can We Cure HBV Infection?

Tram T. Tran, MD and Harry L. Janssen, MD, PhD

EMW-12 Implementation of CDC Recommendations for HBV and HCV Screening

John W. Ward, MD and Seng Gee Lim, MD

EMW-13 Management of Coagulopathies in Chronic Liver Disease

R. Todd Stravitz, MD and Stephen H. Caldwell, MD

EMW-14 Bariatric Surgery in NAFLD

Joel E. Lavine, MD, PhD and Paul D. Berk, MD

Plenary Session

Transplant Plenary I

Sunday, November 3

8:00 - 9:30 AM Hall E/General Session

MODERATORS: David J. Reich, MD

David C. Mulligan, MD

8:00 AM

1:MELD Inflation: The Current Hepatocellular Carcinoma Exception Policy is Primarily Responsible for Steadily Increasing MELD Scores at the Time of Liver Transplant in All Regions of the U.S

Patrick G. Northup, Nicolas M. Intagliata, Neeral L. Shah, Curtis K. Argo

8:15 AM

2: Wait List Time Predicts Survival after Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study in the UNOS Registry

Barry Schlansky, Yiyi Chen, Donald Austin, Willscott E. Naugler

8:30 AM

3: Twice-Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in Genotype 1 HCV Liver Transplant Recipients: Interim Week 16 Safety and Efficacy Results of the Prospective, Multicenter REFRESH Study

Kimberly Ann Brown, Robert J. Fontana, Mark W. Russo, Josh Levitsky, Eric M. Yoshida, Hugo E. Vargas, Mohammad Bsharat, Raymond A. Rubin, Robert S. Brown

8:45 AM

4: Molecular Integrated Approach for Early Biomarkers of HCC Development in Hepatitis C Infected Patients

Daniel Maluf, Ricardo C. Gehrau, Abdullah M. Al-Osaimi, Curtis K. Argo, Stephen H. Caldwell, Valeria Mas

9:00 AM

5: Medication Tradeoffs, Non-Adherence, and Clinical Outcomes among Liver Transplant Recipients

Marina Serper, Kamila Przytula, Rachel E. Patzer, Daniela Ladner, Michael S. Wolf

9:15 AM

6: Magnitude of survival benefit after Liver Transplantation (LT) for metastatic neuroendocrine tumors (NET) of gastroenterol-pancreatic (GEP) origin

Vincenzo Mazzaferro, Carlo Sposito, Rosalba Miceli, Sherrie Bhoori, Tiziana Camerini, Jorgelina Coppa, Enrico Regalia, Carlo Battiston, Marco A. Bongini, Davide Citterio, Carlo Spreafico, Federica Brunero, Filippo de Braud, Luigi Mariani

Poster Session II

Sunday, November 3

8: 00 AM - 5: 30 PM

Hall E

Refer to page 119A for Poster Presentations

Exhibit Hall

Sunday, November 3

9: 30 AM - 3: 00 PM

Hall D

9: 30 - 10: 00 AM

Coffee Break

1: 30 - 2: 00 PM

Snack Break

Basic Research Workshop

Sunday, November 3

8:00 AM - Noon Room 145

Liver Regeneration

COURSE DIRECTORS: Satdarshan (Paul) S. Monga, MD George K. Michalopoulos, MD,

4 CME Credits

The workshop will apprise the investigators who are in the field and those outside of the regeneration field, of the key concepts of the regeneration that will enable collaborations, generate new ideas and thus propel this field forward. The goal of this workshop is to provide a balanced, yet timely overview of the regeneration process.

Regeneration is a process unique to the liver as an adult organ. Following surgical resection or toxin-induced injury, the remnant liver has the capacity to undergo regeneration to compensate for the lost mass. Adult hepatocytes, which are terminally differentiated cells, undergo rounds of proliferation, as do all the other cell types within the adult liver. This in fact is a result of a concerted cellular and molecular effort that drives the repair process. Using different pre-clinical models, it is now clear that multiple and redundant growth factor and cytokines now orchestrate the initiation and progression of the regenerative process, which act in an autocrine, paracrine and endocrine manner. It is highly relevant to understand the role and regulation of such networks that will have significant clinical implications in promoting hepatic repair and regeneration in several pathologies. At the same time, it is critical to identify the termination signals that function as hepatostat to limit hepatic overgrowth and prevent any untoward consequences. In addition to the molecular signaling, cellular mechanisms of regeneration are widely understood and it is clear that multiple cell types including parenchymal and non-parenchymal cells of the liver participate in the repair process. These cells are not just the source of various signaling molecules in a highly temporal manner, but also themselves undergo rounds of replication to eventually restore a functional hepatic mass.

Learning Objectives:

  • Evaluate the many molecular mechanisms of the initiation of the hepatic regeneration along with existing redundancy in the system
  • Appraise the roles of various cell types within the liver as well as non-resident cells to participate and direct the process
  • Review the mechanisms terminating the process of liver regeneration

Session I: Regulation of Regenerative Process in the Liver

MODERATORS: George K. Michalopoulos, MD, PhD

Michael H. Nathanson, MD, PhD

8:00 - 8:20 AM Clinical Implications of Advances in the Basic Science of Liver Repair and Regeneration

Seth J. Karp, MD

8:20 - 8:40 AM Initiation and Termination of Liver Regeneration

George K. Michalopoulos, MD, PhD

8:40 - 9:10 AM Calcium Signaling in Liver Regeneration

Michael H. Nathanson, MD, PhD

9:10 - 9:30 AM Cell Cycle Regulation in Liver Regeneration

Jeffrey H. Albrecht, MD

9:30 - 9:50 AM Metabolic Regulation of Liver Regeneration Process

David A. Rudnick, MD, PhD

9:50 -10:20 AM Break

Session II: Developmental Pathways in Liver Regeneration

MODERATORS: Anna Mae Diehl, MD

Satdarshan (Paul) S. Monga, MD

10:20 -10:40 AM Wnt/β-catenin Signaling in Hepatic Regeneration

Satdarshan (Paul) S. Monga, MD

10:40 - 11:00 AM Hedgehog Signaling in Liver Regeneration

Anna Mae Diehl, MD

11:00 -11:20 AM Origin of New Hepatocytes in Liver Regeneration

Holger Willenbring, MD, PhD

Session III: Non-Parenchymal Cells and Liver Regeneration


David A. Rudnick, MD, PhD

11:20 - 11:40 AM Biliary Cell Participation in Liver Regeneration

Gianfranco Alpini, PhD

11:40 AM - Noon Adaptive Immunity and Liver Regeneration

Robert A. Anders, MD, PhD

Hepatology Associates Course

Hepatology Associates Course

Sunday, November 3

8:00 AM -1:30 PM Room 147


Mary Panther, RN

5.5 CME Credits / 5 Contact Hours

This one day course aims to provide basic and advanced up-to-date knowledge for the management of patients with liver disease.

Learning Objectives:

  • Explain the current nonalcoholic steatohepatitis (NASH) practice guidelines and appropriate, patient specific strategies to treat NASH & nonalcoholic fatty liver disease (NAFLD)
  • Identify patient selection indication for liver biopsy or a non-invasive alternative to stage fibrosis
  • Describe controversial decisions with transplant patient selections and orgean allocations including split vs full liver transplant
  • Discuss benefits and risks of Coffee, CAM and Cannabis in the liver patient
  • Examine complex Hepatitis C (HCV) treatment populations and identify appropriate strategies to manage difficult HCV treatment side effects

8:00 - 8:05 AM Opening Remarks

Session I

MODERATORS: Donald Gardenier, DNP

Linda M. Stadheim, RN

8:05 - 8:45 AM NASH & NAFLD: Cutting Through the Fat

Andrea A. Gossard, NP

8:45 - 8:55 AM Awarded Poster Presentation

Geri Hirsch, MSN, RN-NP and Gail Butt, MD

8:55 - 9:30 AM Biopsy versus Non-invasive Approaches to Assessing Fibrosis

R. Todd Stravitz, MD

9:30 - 9:40 AM Awarded Poster Presentation

Amy Nelson, BSN, RN, ACRN

9:40 - 10:20 AM Liver Transplantation Controversies

Jacqueline Laurin, MD

10:20 - 10:30 AM Discussion

10:30 - 11:00 AM Break and Brunch

Session II

MODERATORS: Mary Panther, RN

Dustin C. Latimer, PA-C

11:00 - 11:45 AM HCV Triple Therapy Lessons Learned

Antonio J. Sanchez, MD

11:45 AM - 12:30 PM Point-Counterpoint: Hepatitis C Treatment

Douglas R. LaBrecque, MD and Paul Y. Kwo, MD

12:30 - 1:00 PM Coffee, CAM and Cannabis: Stirring the Pot

Kiran Bambha, MD

1:00 - 1:30 PM Discussion and Closing

Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture

Sunday, November 3

9:30 - 10:00 AM Hall E/General Session

Regenerative Medicine: New Approaches to Healthcare

SPEAKER: Anthony Atala, MD

MODERATOR: Kenneth D. Chavin, MD, PhD

Patients with diseased or injured organs may be treated with transplanted organs. There is a severe shortage of donor organs which is worsening yearly due to the aging population. Regenerative medicine and tissue engineering apply the principles of cell transplantation, material sciences, and bioengineering to construct biological substitutes that may restore and maintain normal function in diseased and injured tissues. Stem cells may offer a potentially limitless source of cells for tissue engineering applications and are opening new options for therapy. Recent advances that have occurred in regenerative medicine will be reviewed and applications of these new technologies that may offer novel therapies for patients with end-stage tissue and organ failure will be described. The emphasis will be on basic knowledge.

Anthony Atala, MD, is Director of Wake Forest Institute for Regenerative Medicine and Chair of Urology at Wake Forest School of Medicine. He is a practicing surgeon and a researcher in regenerative medicine. He is Editor-in-Chief of Stem Cells-Translational Medicine and Therapeutic Advances in Urology, and serves on the editorial board of 20 journals. He has received the Christopher Columbus Award, World Technology Award in Medicine, Samuel Gross Prize, Barringer Medal, and Gold Cystoscope award. His medical breakthroughs have been featured in Time magazine and U.S. News & World Report. He is the editor of 12 books, has published over 300 journal articles, and has over 40 patents.

Learning Objectives:

  • Describe the field of tissue engineering and regenerative medicine
  • Explain current research and clinical applications in regenerative medicine

The Thomas E. Starzl Transplant Surgery Stateof-theArt Lecture recognizes the pioneering work that Dr. Thomas E. Starzl and colleagues have done to elevate liver transplantation from experimental procedure to one which saves thousands of lives annually. To ensure that future transplant scientists have a distinct platform to provide their valuable insights at The Liver Meeting®, a restricted fund has been established to support this lecture in perpetuity. AASLD gratefully acknowledges the following individuals and organizations that have generously contributes to this fund:


Astellas Pharma US, Inc.

Clyde F. Barker, MD

Adel Bozorgzadeh, MD

Pradip Chakrabarti, MD

Chao-Long Chen, MD

David K. C. Cooper, MD

Bijan Eghtesad, MD

Ira J. Fox, MD

John J. Fung, MD, PhD

Ashokkumar B. Jain, MD

Zakiyah Kady MD

Dympna Kelly, MD

Charles M. Miller, MD

Ernesto P. Molmenti, MD

Michael C. Morris, MD

Eduardo A. Santiago-Delpin, MD

Byers W. Shaw, Jr., MD

Cynthia A. Smetanka, MD

Lewis Teperman, MD

Paul Terasaki, MD

Exhibit Hall D

10:00 -10:30 AM

Coffee Break

Plenary Session

Transplant Plenary II

Sunday, November 3

10:30 AM - Noon Hall E/General Session

MODERATORS: Kenneth D. Chavin, MD, PhD

Susan L. Orloff, MD

10:30 AM

7: De novo donor-specific anti-HLA antibodies are a risk factor for graft loss in DCD liver transplantation

Oya Andacoglu, Thomas Ellis, Anthony M. D'Alessandro, David Foley, Amy Powell, Glen E. Leverson, Michael R. Lucey, Alexandru I. Musat

10:45 AM

8: Ex-vivo hepatic perfusion with a new cell-free oxygen carrier solution upregulates hepatocyte associated gene response against ischemia-reperfusion injury and triggers protective and regenerative pathways

Paulo A. Fontes, Shirish Paranjpe, William R. Light, George K. Michalopoulos

11:00 AM

9: Prognostic cell-based assay predicts acute cellular rejection in pre- and post transplant testing of children with liver and intestine transplantation (LTx, ITx)

Chethan Ashokkumar, Rafia Khan, Kyle A. Soltys, Geoffrey Bond, George V. Mazariegos, Brandon W. Higgs, Rakesh Sindhi

11:15 AM

10: Putative miRNA signatures indicative of Fatal acute liver failure and Survival in HEV infection in pregnancy

Nirupma Trehanpati, Rashi Sehgal, Paul David, Ashish Vyas, Ritu Khosla, Shiv K. Sarin

11:30 AM

11:Intention-to-treat Outcome of T1 Hepatocellular Carcinoma Using the Approach of “Wait and not Ablate” until Meeting T2 Criteria for Liver Transplant Listing

Neil Mehta, Jennifer L. Dodge, Nicholas Fidelman, John P. Roberts, Francis Y. Yao

11:45 AM

12: Increased Rates of Liver Transplant Wait-Listing for Hepatocellular Carcinoma in Individuals with Hepatitis C from 2003 - 2010 in the United States

Jennifer A. Flemming, W. Ray Kim, Eric Vittinghoff, Carol L. Brosgart, Kris V. Kowdley, Norah Terrault

Hans Popper Basic Science State-of-the-Art Lecture

Sunday, November 3

Noon - 12:30 PM Hall E/General Session

Alpha-1 Antitrypsin Deficiency: Novel Treatment Strategies Fifty Years After Discovery

SPEAKER: David H. Perlmutter, MD

MODERATOR: Ronald J. Sokol, MD

This lecture will describe the history of the disease, what we have learned about its unique clinical sequellae and novel treatment strategies that have originated from understanding the unique pathabiology.

David H. Perlmutter, MD is the Vira I Heinz Endowed Chair of the Department of Pediatrics at the University of Pittsburgh School of Medicine. He is Distinguished Professor of Pediatrics and Professor of Cell Biology at the University and Physician-in-Chief and Scientific Director of Children's Hospital of Pittsburgh of UPMC. Dr. Perlmutter earned his BA from the University of Rochester and his MD from St. Louis University School of Medicine. He trained in Pediatrics at Children's Hospital of Philadelphia and in Pediatric Gastroenterology and Nutrition at Children's Hospital, Boston. After several years on the faculty of Harvard Medical School he joined the faculty at Washington University School of Medicine and St. Louis Children's Hospital. From 1992-2001 Dr. Perlmutter was the Director of the Division of Gastroenterology and Nutrition at St. Louis Children's and in 1996 he became the first to hold the Donald Strominger Endowed Professorship of Washington University School of Medicine. In 2001 he left St. Louis to take his current position in Pittsburgh.

Dr. Perlmutter has carried out basic research on alpha-1-antitrypsin deficiency for over 25 years. His work has led to many new concepts about the pathobiology of liver disease in this deficiency and has suggested several new concepts for chemoprophylaxis of chronic liver injury, hepatocellular carcinoma and emphysema in this genetic disease. In 2010 he discovered a new pharmacological strategy that prevents liver damage in a mouse model of alpha- 1-antitrypsin deficiency and that strategy is now being tested in Phase II/III clinical trials. He has been continuously funded by NIH including 4 current investigator-initiated grants on aspects of alpha- 1-antitrypsin deficiency, a T32 fellowship training grants and a K12 Child Health Research Center of Excellence Award for training pediatric physician scientist in the molecular basis of pediatric disease. Dr. Perlmutter's research has been recognized by numerous awards including the E Mead Johnson Award for Research in Pediatrics. He is a member of the American Society for Clinical Investigation and the Association of American Physicians and was elected to the Institute of Medicine of the National Academy of Sciences in 2008. He has served as the President of the Society of Pediatric Research and as a member of the Advisory Council of the National Institute for Diabetes, Digestive and Kidney Diseases. He is a member of numerous other advisory boards, foundation boards and editorial boards. Since joining Children's Hospital in 2001, Dr. Perlmutter has led an effort to expand the hospital's basic and clinical research program so that it is ideally poised to investigate the molecular basis of disease and to develop innovative therapies. CHP is now one of the fastest growing pediatric research programs in the country in terms of NIH funding.

Learning Objectives:

  • Explain how accumulation of mutant antitrypsin in liver cells is proteotoxic, leading to fibrosis and carcinogenesis in the classical form of alpha-1-antitrypsin deficiency
  • Identify how a similar mechanism may contribute to lung disease in the classical form of alpha-1-antitrypsin deficiency

The Hans Popper Basic Science State-of-the-Art lecture recognizes Hans Popper, the founder of AASLD, his role in the establishment of the AASLD journal, HEPATOLOGY, and his promotion of the intellectual spirit of the Association.

Celebrating the 50th Anniversary of the discovery of Alpha-1 Antitrypsin Deficiency

Federal Focus

Sunday, November 3

1:00 - 5:00 PM Room 151

Alcoholic Liver Disease

MODERATORS: Laura E. Nagy, PhD

Craig J. McClain, MD

4 CME Credits

Alcohol abuse is a leading cause of morbidity and mortality worldwide. In the US, approximately 18 million people abuse alcohol, and alcoholic liver disease (ALD) affects over 10 million people. Alcohol's deleterious effects on the liver lead to pathologically distinct entities: steatosis, alcoholic hepatitis (AH), fibrosis, cirrhosis and hepatocellular carcinoma. AH, characterized by progressive negro-inflammation, is a particularly serious form of liver disease, with a very high short term mortality rate of ∼40%. Survivors are at an increased risk for the development of liver fibrosis and cirrhosis. Presentations by basic, translational and clinical investigators will provide updates and insights into recent research that continues to improve our understanding of the pathophysiological mechanisms for disease progression and the identification of rationally-designed prevention and treatment strategies. Federal support for research on alcoholic liver disease has primarily been through the National Institutes of Alcoholism and Alcohol Abuse (NIAAA). The Department of Defense and the Federal Drug Administration also have ongoing interests in programs related to alcoholic hepatitis. Representatives from these federal agencies will discuss their focus and roles for federal support in the management of alcoholic liver disease, as well as in the development of novel diagnostic, therapeutic and management strategies for patients with alcoholic liver disease.

Learning Objectives:

  • Explain the latest insights into the molecular and cellular mechanisms for ALD
  • Define the current challenges in the diagnosis and treatment of ALD
  • Identify different federal agencies interested in research on alcoholic hepatitis and alcoholic liver disease
  • Discuss the role of drug discovery and complementary medicine in ALD

Session I: Clinical and Translational Research: Focus on Severe Acute Alcoholic Hepatitis

MODERATORS: Craig J. McClain, MD

Samir Zakhari, PRD

1:00 - 1:20 PM Development of Improved Scoring Methods for the Diagnosis and Treatment of Severe Acute Alcoholic Hepatitis

Philippe Mathurin, MD, PhD

1:20 -1:25 PM Q&A

1:25 - 1:45 PM Acute Complications in ASH: Role in Prognosis and Treatment Strategies

Ramón Bataller, MD

1:45 - 1:50 PM Q&A

1:50 - 2:10 PM Towards Personalized Medicine: Development of Biomarkers for Improved Therapeutics In ALD

Christopher Leptak, MD, PhD

2:10 - 2:15 PM Q&A

2:15 - 2:45 PM Panel Discussion: Funding Opportunities to Support Research on ALD

Gary J. Murray, PhD and Kenneth R. Warren, PhD

2:45 - 3:05 PM Break

Session II: Basic Mechanisms: Focus on Inter-organ Interactions in ALD

MODERATORS: Laura E. Nagy, PhD

Ali Keshavarzian, MD

3:05 - 3:25 PM Dysregulation of the Gut Microbiome in ALD

Bernd Schnabl, MD

3:25 - 3:30 PM Q&A

3:30 - 3:50 PM Monocyte Recruitment to the Liver and Adipose in ALD

Cynthia Ju, PhD

3:50 - 3:55 PM Q&A

Panel discussion: NIAAA Funded UO1 Translational Research in Alcoholic Hepatitis

MODERATORS: Laura E. Nagy, PhD

Craig J. McClain, MD

3:55 - 4:05 PM Goals and Structure of UO1 Translational Research in Alcoholic Hepatitis

Gary J. Murray, PhD

Brief overview: Aims by each of the funded consortiums

4:05 - 4:15 PM David W. Crabb, MD

4:15 - 4:25 PM Gyongyi Szabo, MD, PhD

4:25 - 4:35 PM Ramón Bataller, MD

4:35 - 4:45 PM Timothy R. Morgan, MD

4:45 - 5:00 PM Q&A for NIAAA Panel/Consortia

President's Choice

Sunday, November 3

2:00 - 2:30 PM Hall E/General Session

Random Germline Mutagenesis in the Analysis of Immunity

SPEAKER: Nobel Laureat, Bruce A. Beutler, MD

MODERATOR: J. Gregory Fitz, MD

This lecture will describe how a classical genetic approach can be used to provide a list of the causes of inherited disease; how it has become practical to saturate the genome of the mouse with mutations and assigns cause and effect.

Bruce Beutler is a Regental Professor and Director of the Center for the Genetics of Host Defense at UT Southwestern Medical Center in Dallas, Texas. In 2011, he shared the Nobel Prize in Physiology or Medicine for “discoveries concerning the activation of innate immunity.”

Dr. Beutler received his medical training at the University of Chicago, graduating in 1981. As a postdoctoral fellow at The Rockefeller University (1983-1986), he isolated mouse tumor necrosis factor (TNF) and discovered its importance as a mediator of inflammation. Subsequently, at UT Southwestern, he analyzed mammalian responses to bacterial lipopolysaccharide. This work culminated in the identification of Toll-like receptors as key sensors of the innate immune system, used to detect infection. In further studies, Beutler employed a forward genetic strategy to elucidate many aspects of mammalian immunity. In addition to the Nobel Prize, he has received many other awards for his work, a partial list of which includes the Balzan Prize (2007), the Albany Medical Center Prize (2009), the Shaw Prize (2011), the Korsmeyer Award (2013), and election to both the US National Academy of Sciences and the Institute of Medicine (2008). Beutler is also a member of the German Academy of Sciences (Leopoldina) and of the French Legion d'Honneur.

Learning Objectives:

  • Discuss how the immune system operates, particularly with respect to the production of antibodies against and infectious agent
  • Create and solve immune diseases using a germline mutagen
  • Identify parallels between the mouse and human where immune function is concerned

Exhibit Hall D

1:30 - 2:00 PM

Snack Break

AASLD Distinguished Awards

Sunday, November 3

2:45 - 3:00 PM Hall E/General Session

AASLD Distinguished Clinician Educator/Mentor Award

Presented to: Arthur J. McCullough, MD

Presented by: Anthony S. Tavill, MD

General Hepatology Update

Sunday, November 3

3:00 - 4:30 PM Ballroom AB

General Hepatology Update

MODERATORS: Ester C. Little, MD

Paul Angulo, MD

1.5 CME Credits

This annual forum is intended to provide hepatologists an update on the diagnosis and management of three clinically relevant topics that are commonly encountered in routine clinical practice. Issues including diagnostic strategies and approaches to management are reviewed to provide state-of-the-art guidelines particularly for diagnostic dilemmas.

Learning Objectives:

  • Describe the current guidelines for the diagnosis and management of hepatocellular carcinoma
  • Identify the most common drugs that can cause liver damage and understand the mechanisms of liver toxicity
  • Discuss the current guidelines for the diagnosis and management of Primary Biliary Cirrhosis

3:00 - 3:25 PM Update on Management of Hepatocellular Carcinoma

Jorge A. Marrero, MD

3:25 - 3:50 PM Drug-induced Liver Injury Update

Paul B. Watkins, MD

3:50 - 4:15 PM PBC

Keith D. Lindor, MD

4:15 - 4:30 PM Discussion

Parallel Session

Parallel 1:Biliary Atresia and Neonatal Cholestasis

Sunday, November 3

3:00 - 4:30 PM Room 146A

MODERATORS: Regino P. Gonzalez-Peralta, MD

Ronald J. Sokol, MD

3:00 PM

13: ARF6 gene dysregulation may contribute to biliary dysgenesis in biliary atresia (BA)

Mylarappa Ningappa, Joseph Glessner, Johoon So, Donghun Shin, Chethan Ashokkumar, Hakon Hakonarson, Rakesh Sindhi

3:15 PM

14: Diagnostic and Predictive Value of Serum Biomarkers in Biliary Atresia

James E. Squires, Kazuhiko Bessho, Lin Fei, Reena Mourya, Pranavkumar Shivakumar, John C. Magee, Jorge A. Bezerra

3:30 PM

15: Elevated effector and target cell transmembrane Tnfα regulates mucosal injury in experimental biliary atresia

Pranavkumar Shivakumar, James E. Squires, Stephanie Walters, Jorge A. Bezerra

3:45 PM

16: Hepatic Phytosterol Accumulation During Parenteral Nutrition Involves Activation of Macrophages and Cytokine-mediated Suppression of Hepatocellular Sterol Export Systems (ABCG5/8)

Padade Vue, Aimee Anderson, Michael W. Devereaux, Natarajan Balasubramaniyan, Ronald J. Sokol, Karim C. El Kasmi

4:00 PM

17: FXR-mediated Signaling is Impaired in iPS-derived Hepatocytes in PFIC1 (Byler) Disease and is Enhanced by 4-Phenylbutyrate

Bing Han, Edgar N. Tafaleng, Frank Chen, Alexandra Dreyzin, Benjamin L. Shneider, Ira J. Fox

4:15 PM

18: Cost-effective analysis of screening for biliary atresia with the stool color card

Douglas Mogul, Mo Zhou, Paul Intihar, Kathleen B. Schwarz, Kevin Frick

Parallel 2: Epidemiology of Viral Hepatitis

Sunday, November 3

3:00 - 4:30 PM Room 147

MODERATORS: Robert J. Fontana, MD

Joseph Ahn, MD, MS

3:00 PM

19: Effects of chronic hepatitis C on pregnancy and perinatal outcomes

Po-Hung Chen, Berkeley N. Limketkai, Brian Kim, Tinsay A. Woreta

3:15 PM

20: Development of Hepatitis C Virus infection associated B-Cell Non-Hodgkin Lymphoma is mediated by downregulation of the tumor-suppressive microRNA miR-26b

Jan Peveling-Oberhag, Benjamin Rengstl, Frederic C. Chatain, Kyoko Tsukiyama-Kohara, Marco Lucioni, Marco Paulli, Stefan Zeuzem, Martin Leo Hansmann

3:30 PM

21:Hepatitis C Virus Screening and Prevalence among US Veterans in Department of Veterans Affairs Care in

Lisa I. Backus, Pamela S. Belperio, Timothy P. Loomis, Troy A. Shahoumian, Larry A. Mole

3:45 PM

22: Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated With Boceprevir or Telaprevir

Andrew Aronsohn, Tuesdae Stainbrook, Smruti Mohanty, Abdullah Mubarak, James Spivey, Prashant K. Pandya, Thomas Stewart, Michael W. Fried, Ira M. Jacobson

4:00 PM

23: The global burden of liver disease attributable to hepatitis B, hepatitis C, and alcohol: increasing mortality, differing causes

Benjamin C. Cowie, Jennifer H. MacLachlan

4:15 PM

24: Hepatitis C Virus (HCV) Antibody Positivity and Predictors among Adult Primary Care Patients: CrossSectional Analysis of a Multi-Site Retrospective Cohort Study

Anthony K. Yartel, David B. Rein, Katherine Krauskopf, Omar I. Massoud, Kimberly Ann Brown, Michael B. Fallon, Bryce D. Smith

Parallel 3: Fibrosis: Basic Mechanisms and Novel Therapeutics

Sunday, November 3

3:00 - 4:30 PM Room 150A

MODERATORS: Bryan Copple, PhD

Christian Trautwein, MD

3:00 PM

25: Targeting lysyl oxidase like 2 (LOXL2) inhibits collagen cross-linking and accelerates reversal of preestablished liver fibrosis

Naoki Ikenaga, Shuhei Yoshida, Susan B. Liu, Jeanhee Chung, Deanna Sverdlov, Derek Marshall, Vivian Barry, Victoria Smith, Maria Kovalenko, Satyajit Karnik, Nezam H. Afdhal, Yury Popov

3:15 PM

26: Proteomic Analysis Identifies P90rsk as a Novel Mediator of Liver Injury in Alcoholic Hepatitis

Oriol Morales-Ibanez, Silvia Affo, Daniel Rodrigo-Torres, Cristina Millan, Montserrat Moreno, Vicente Arroyo, Pere Gines, Juan Caballeria, Pau Sancho-Bru, Ramon Bataller

3:30 PM

27: Post-translational Control of Methionine Adenosyltransferases during Human Hepatic Stellate Cell Trans-differentiation

Komal Ramani, Shant Donoyan, Maria Lauda Tomasi, Sunhee Park

3:45 PM

28: MicroRNA-214 -mediated suppression of connective tissue growth factor (CTGF) in hepatic stellate cells is associated with stimulation of miR-214 promoter activity by cellular or exosomal Twist-1

Li Chen, Alyssa Charrier, David Brigstock

4:00 PM

29: Hepatocyte NOX4 plays an important role in modulating stress response-mediated fibrogenic injury during NASH

Tzu-I Chao, Xiaosong Jiang, Hiroo Fukada, Fawaz Haj, Ahmed Bettaieb, Natalie Torok

4:15 PM

30: Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH

Eric Lefebvre, Taishi Hashiguchi, Helen Jenkins, Antoun Nabhan, Hiroyuki Yoneyama, Scott L. Friedman, Grushenka H. Wolfgang

Parallel 4: HBV Treatment

Sunday, November 3

3:00 - 4:30 PM Room 145


David E. Kaplan, MD

3:00 PM

31:96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study

Heiner Wedemeyer, Cihan Yurdaydin, Stefanie Ernst, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gurel, Stefan Zeuzem, Andreas Erhardt, Stefan Lüth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Mustafa K. Celen, Judith Stift, Benjamin Heidrich, Ingmar Mederacke, Svenja Hardtke, Armin Koch, Hans P. Dienes, Michael P. Manns

3:15 PM

32: Comparative Effectiveness of Entecavir and Lamivudine on Survival of Patients with Chronic Hepatitis B Virus Infection

Young-Suk Lim, Nae-Yun Heo, Seungbong Han, Jihyun An, Gi Ae Kim, Dong Jin Suh

3:30 PM

33: TG1050, a viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses with properties similar to those displayed by HBV resolving patients and has an early antiviral effect in a HBV tolerant model

Perrine Martin, Clarisse Dubois, Emilie Jacquier, Alexei Evlachev, Houda Boukhebza, Sarah Dion, Maryline Mancini-Bourgine, Ophélie Godon, Annie Findeli, Yasmin Schlesinger, Renee Brandely, Jean-Baptiste Marchand, Thierry Menguy, Nathalie Silvestre, Marie-Louise Michel, Genevieve Inchauspe

3:45 PM

34: Interim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study

Wai-Kay Seto, Thomas Sau Yan Chan, Yu-Yan Hwang, Olivia Choi, Danny Wong, James Fung, Albert Kwok-Wai Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen

4:00 PM

35: Low serum IL-10 and HBsAg concentrations are associated with long-term immune control in persistent HBV-infection

Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Magdalena widerska, Magdalena Rogalska-Plonska, Tadeusz W. Lapinski, Robert Flisiak

4:15 PM

36: Nucleoside Analogs Prevent Disease Progression in HBV-Related Acute-on-Chronic Liver Failure: Validation of the TPPM Model

Ke Ma, Junshuai Wang, Meifang Han, Wei Guo, Jiaquan Huang, Daofeng Yang, Xiping Zhao, Jianxin Song, Deying Tian, Junying Qi, Yuancheng Huang, Qin Ning

Parallel 5: HCV Therapeutics: Real World Experience

Sunday, November 3

3:00 - 4:30 PM Hall E/General Session

MODERATORS: Richard K. Sterling, MD, MSc

Stevan A. Gonzalez, MD

3:00 PM

37: Antiviral Treatment for Hepatitis C Virus in HIV/HCV Co-infected Patients

George N. Ioannou, John D. Scott, Yin Yang, Pamela Green, Lauren A. Beste

3:15 PM

38: Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV

Marisa Montes, Mark Nelson, Marie Girard, Joe Sasadeusz, Andrzej Horban, Beatriz Grinsztejn, Natalia Zakharova, Karolin Falconer, Inge Dierynck, Donghan Luo, Yi-Wen Ma, James Witek

3:30 PM

39: Differential Impact of Type 1 Interferon on Chronic Hepatitis C Infection in HIV Co-infection, Pre- and Post- HAART

Ashwin Balagopal, Abraham J. Kandathil, Johnanathan Wood, Fuat Kurbanov, Jeffrey Quinn, Justin Richer, Yvonne M. Higgins, Lois Eldred, Zhiping Li, Mark S. Sulkowski, David L. Thomas

3:45 PM

40: Telaprevir in the Treatment of Acute HCV Infection in HIV-infected Men: SVR 12 Results

Daniel S. Fierer, Douglas T. Dieterich, Michael P. Mullen, Andrea D. Branch, Alison J. Uriel, Damaris C. Carriero, Wouter O. van Seggelen, Rosanne M. Hijdra, David Cassagnol

4:00 PM

41:Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET)

Adrian M. Di Bisceglie, Alexander Kuo, Vinod K. Rustgi, Mark S. Sulkowski, Richard K. Sterling, Thomas Stewart, Michael W. Fried, Jonathan M. Fenkel, Hisham ElGenaidi, Mitchell A. Mah'moud, George M. Abraham

4:15 PM

42: Serious Adverse Drug Reactions Related to Boceprevir: Analysis of Food and Drug Administration Reported Events

Bryan L. Love, Vishvas Garg, Rasha Arabyat, Dennis W. Raisch, Charles L. Bennett

Parallel 6: Living Donors Transplantation and Hepatic Resection

Sunday, November 3

3:00 - 4:30 PM Room 152A

MODERATORS: James Trotter, MD

Elizabeth A. Pomfret, MD, PhD

3:00 PM

43: Pain Management in Living Liver Donors

Daniela Ladner, Robert A. Fisher, Elizabeth A. Pomfret, Mary Ann Simpson, Robert S. Brown, Amna Daud, Kathryn Waitzman, John R. Joseph, Donna Woods

3:15 PM

44: Activation of the Constitutive Androstane Receptor (CAR) reverses deficient liver regeneration in the Small-For-Size Syndrome via Foxm1b and miR375/YAP-dependent pathways

Christoph Tschuor, Ekaterina Kachaylo, Perparim Limani, Amedeo Columbano, Andrea Schlegel, Jae Hwi Jang, Dimitri A. Raptis, Emmanuel Melloul, Yinghua Tian, Rolf Graf, Bostjan Humar, Pierre A. Clavien

3:30 PM

45: Comparison of surgical outcome between minimally invasive liver resection and conventional open liver resection for the treatment of hepatocellular carcinoma : a propensity-score matched analysis

Dai Hoon Han, Eun Jung Park, Gi Hong Choi, Jin Sub Choi

3:45 PM

46: The impact of nonalcoholic steatohepatitis on the prognosis of patients with hepatocellular carcinoma within the Milan criteria and underwent resection surgery

Chien-Wei Su, Gar-Yang Chau, Jaw-Ching Wu, Hung-Hsu Hung, Hao-Jan Lei, Han-Chieh Lin, Shou-Dong Lee

4:00 PM

47: Dual Treatment; A Novel Strategy for Highly-Advanced Hepatocellular carcinoma

Shinichi So, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yonson Ku

4:15 PM

48: “Small for Size Syndrome” (SFSS) after Living Donor Liver Transplantation (LDLT): It's Not About Size. Report from the Adult to Adult Living Donor Liver Transplantation (A2ALL) Cohort Study

James Pomposelli, Abhinav Humar, Talia B. Baker, David Grant, Nathan P. Goodrich, Brenda W. Gillespie, Robert M. Merion, Igal Kam, Michael A. Zimmerman, Benjamin Samstein, Peter L. Abt, Chris Freise, Jean C. Emond

Parallel 7: Pathological Mechanisms in NAFLD

Sunday, November 3

3:00 - 4:30 PM Ballroom C

MODERATORS: Richard Green, MD

Ariel E. Feldstein, MD

3:00 PM

49: Maternal obesity promotes offspring non-alcoholic fatty liver disease (NAFLD) through disruption of endoplasmic reticulum homeostasis

Junpei Soeda, Angelina Mouralidarane, Esra Asilmaz, Shuvra Ray, Joaquim Pombo, Lucilla Poston, Paul D. Taylor, Jude A. Oben

3:15 PM

50: Hepatic Gap Junction Inhibition Limits Liver Injury and Inflammation in Non-alcoholic Steatohepatitis

Suraj J. Patel, Jay Luther, Kevin R. King, Stefan Bohr, John Scichilone, John Garber, Lee F. Peng, Raymond T. Chung, Martin L. Yarmush

3:30 PM

51:A lipotoxic mechanism of NASH: Free cholesterol causes hepatocyte apoptosis and necrosis by JNK-mediated mitochondrial injury, and resultant release of hepatocyte-derived HMGB1 and microparticles activate Kupffer cells

Lay Gan, Derrick M. Van Rooyen, Mark Koina, Robert S. McCuskey, Narci Teoh, Geoffrey C. Farrell

3:45 PM

52: Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis

Sophie C. Cazanave, Xuan Wang, Huiping Zhou, Curtis D. Klaassen, Arun J. Sanyal

4:00 PM

53: Role of the IL-17 axis in the development and progression of non-alcoholic fatty liver disease

Daniel Giles, Traci Stankiewicz, Isaac T. Harley, Monica Cappelletti, Samir Softic, Stavra A. Xanthakos, Rohit Kohli, Christopher L. Karp, Senad Divanovic

4:15 PM

54: Short Heterodimer Partner (SHP) is necessary for the Improvement in NASH after Sleeve Gastrectomy in Obese Mice

Andriy Myronovych, Rosa-Maria Salazar-Gonzalez, Lili Miles, Karen K. Ryan, Randy J. Seeley, Rohit Kohli

Parallel 8: Stem Cells and Progenitors

Sunday, November 3

3:00 - 4:30 PM Room 152B

MODERATORS: Anna Mae Diehl, MD

Chinweike Ukomadu, MD, PhD

3:00 PM

55: Nrf2 Deficiency Causes Transient but Massive Hepatocyte Dedifferentiation during Liver Regeneration

Yuhong Zou, Joonyong Lee, Shashank M. Nambiar, Min Hu, Qi Bao, Guoli Dai

3:15 PM

56: lncRNA MALAT1 inhibits Smad2/3 signaling in hepatic cells

Jinqiang Zhang, Chang Han, Kyoungsub Song, Tong Wu

3:30 PM

57: Regression of cirrhosis: The maturation sequence of buds arising from hepatocyte progenitor cells

Ashley E. Stueck, Ian R. Wanless

3:45 PM

58: Epigenetic Reprogramming Modulates Malignant Properties of Human Liver Cancer Cells

Chiara Raggi, Valentina M. Factor, Seo Daekwan, Agnes Holczbauer, Jens U. Marquardt, Snorri S. Thorgeirsson

4:00 PM

59: Myofibroblastic Cells Function as Progenitors to Regenerate Murine Livers after Partial Hepatectomy

Marzena Swiderska-Syn, Wing-Kin Syn, Guanhua Xie, Leandi Kruger, Anna Mae Diehl

4:15 PM

60: Hepatic Stellate Cells Are the Dominant Source of Myofibroblasts Across all Types of Chronic Liver Injury but do not Contribute to the Generation of Hepatocytes

Ingmar Mederacke, Christine C. Hsu, Juliane Tröger, Peter Huebener, Dianne H. Dapito, Pradere Jean-Philippe, Robert Schwabe

Parallel 9: Viral Hepatitis and Liver Transplantation

Sunday, November 3

3:00 - 4:30 PM Room 146BC

MODERATORS: Ashwani K. Singal, MD, MS

Sandy Feng, MDPhD

3:00 PM

61:Etiologies and Outcomes of Acute Liver Failure in HIV + Adults: Results from the ALFSG Registry

Heather N. Simpson, TimothyJ. Davern, K. Rajender Reddy, Adrian Reuben, Valerie Durkalski, William M. Lee, Robert J. Fontana

3:15 PM

62: Aspirin reduces liver fibrosis progression in hepatitis C recurrence after liver transplantation

Armelle Poujol-Robert, Pierre-Yves Boëlle, Filomena Conti, Francois Durand, Christophe Duvoux, Dominique Wendum, Valerie Paradis, Vincent Mackiewicz, Olivier Chazouillères, Raoul Poupon

3:30 PM

63: Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: A Canadian multicentre experience

Nabiha Faisal, Eberhard L. Renner, Marc Bilodeau, Eric M. Yoshida, Philip Wong, Mang M. Ma, Kelly W. Burak, Bandar Al-Judaibi, Curtis Cooper, Thomas Shaw-Stiffel, Les Lilly

3:45 PM

64: Ten-year follow-up of a randomized study comparing Lamivudine vs Lamivudine+HBIG for the prevention of Hepatitis B virus recurrence after liver transplantation

Maria Buti, Antoni Mas, Martin Prieto, Fernando Casafont, Antonio Gonzalez, Manuel Miras, Jose Ignacio Herrero, Lluis Castells, Rafael Esteban

4:00 PM

65: Scavenger receptor B-I antagonist ITX5061 modulates early HCV kinetics in patients undergoing liver transplantation: results of a phase Ib clinical trial

Ian A. Rowe, Matthew J. Armstrong, Richard Parker, Kathy Guo, Darren Barton, Gene D. Morse, Jeff McKelvy, Flossie Wong-Staal, David H. Adams, Jane A. McKeating, David J. Mutimer

4:15 PM

66: Guillain-Barre syndrome and hepatitis E virus infection

Suzan D. Pas, Bianca van den Berg, Richie G. Madden, Jeremy G. Hunter, Anne P. Tio-Gillen, Harry Dalton, Annemiek A. van der Eijk, Bart C. Jacobs

ABIM Maintenance of Certification

Sunday, November 3

4:00 - 6:00 PM Room 150B

ABIM Maintenance of Certification

MODERATORS: Richard K. Sterling, MD, MSc

Victor I. Machicao, MD

2 CME Credits

The 25 questions Hepatology Medical Knowledge Module will be reviewed using an audience response system. By the completions of the activity participants should be able to successfully complete the ABIM Hepatology module for 10 points of Maintenance of Certification (MOC) credit.

Learning Objectives:

  • Identify gaps in hepatology medical knowledge and target study to address gaps through an interactive forum
  • Recognize the clinical manifestations, pathophysiology, and treatment of many known forms of liver disease
  • Use current, evidence-based practice guidelines and treatment recommendations to guide diagnosis and treatment of liver diseases

4:00 - 4:05 PM Introduction

4:05 - 5:00 PM Session I

Richard K. Sterling, MD, MSc

5:00 - 5:55 PM Session II

Victor I. Machicao, MD

5:55 - 6:00 PM Wrap-up

Parallel Session

Parallel 10: From Genes to Function

Sunday, November 3

4:45 - 6:15 PM Room 152B

MODERATORS: Carol A. Casey, PhD

Jacquelyn J. Maher, MD

4:45 PM

67: Fibrinogen-like protein 1 is a hepatoprotectant

Chinweike Ukomadu, Anal Desai, Valeriy Demchev, Hamed Nayeb-Hashemi, Agoston Agoston, Xintong Chen, Joana F. Neves, Richard S. Blumberg, Yujin Hoshida

5:00 PM

68: Integrative genomic analyses of human fibrolamellar hepatocellular carcinoma

Helena Cornella, Clara Alsinet, Ke Hao, Laia Cabellos, Alberto Quaglia, Zhongyang Zhang, Xintong Chen, Augusto Villanueva, Yujin Hoshida, Nasra H. Giama, David M. Nagorney, Swan N. Thung, Stephen C. Ward, Leonardo Rodriguez-Carunchio, Anja Lachenmayer, Beatriz Minguez, Lewis R. Roberts, Vincenzo Mazzaferro, Myron Schwartz, Nigel Heaton, Josep M. Llovet

5:15 PM

69: Targeting PRAJA1 to govern TERT gene regulation via TGF-β signaling pathway in hepatocellular cancer

Jian Chen, Jiun-Sheng Chen, Vivek Shukla, Zhixing Yao, Wilma Jogunoori, Bibhuti Mishra, Lopa Mishra

5:30 PM

70: KLF14 transcriptionally activates sphingosine kinase 1 and sphingosine-1-phosphate production in response to FGF2 in liver endothelial cells linking metabolic syndrome with hepatic stellate cell activation

Thiago de Assuncao, Sheng Cao, Gwen Lomberk, Usman Yaqoob, Yan Bi, Angela Mathison, Raul A. Urrutia, Vijay Shah

5:45 PM

71:Activity of NMDA Receptors and Roles in Hepatic Injury Offer Novel Mechanisms for Liver Diseases and Therapeutic Development

Nicole Pattamanuch, Preeti Viswanathan, Sylvia O. Suadicani, David C. Spray, Sanjeev Gupta

6:00 PM

72: Hepatic Lipid Droplet Metabolism is Dependent upon Autophagic Lysosomal Dynamics that are Regulated by the Large GTPase Dynamin 2

Ryan Schulze, Shaun Weller, Barbara Schroeder, Eugene W. Krueger, Susan Chi, Carol A. Casey, Mark A. McNiven

Parallel 11:HCV Therapeutics: New Agents

Sunday, November 3

4:45 - 6:15 PM Hall E/General Session


Michael W. Fried

4:45 PM

73: Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin: the ELECTRON

Edward J. Gane, Catherine A. Stedman, Robert H. Hyland, Xiao Ding, Evguenia S. Svarovskaia, Phil S. Pang, William T. Symonds

5:00 PM

74: The Combination of Alisporivir with an NS5A Inhibitor Provides Additive to Synergistic Antiviral Activity, no Cross-Resistance and a High Barrier to HCV Resistance

Udayan Chatterji, Kelly A. Wong, Weidong Zhong, Clifford Brass, Nikolai V. Naoumov, Philippe Gallay

5:15 PM

75: Interferon- and Ribavirin-free Regimen of ABT- 450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders

Eric Lawitz, Christophe Hezode, Peter Varunok, Paul J. Thuluvath, Tolga Baykal, Mudra Kapoor, Sandra S. Lovell, Tianli Wang, Tami Pilot-Matias, Regis A. Vilchez, Barry Bernstein

5:30 PM

76: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study

Eric Lawitz, John M. Vierling, Abel Murillo, Marcelo Kugelmas, Jan Gerstoft, Peter Winkle, Luis A. Balart, Peer B. Christensen, Reem H. Ghalib, Ronald Nahass, Melissa Shaughnessy, Xiao Sun, Peggy Hwang, Janice Wahl, Michael Robertson, Barbara Haber

5:45 PM

77: Preclinical Evaluation of TT-034 - Safe and Durable Hepatic Expression of Anti-HCV shRNA in a NonHuman Primate Model

Shih Chu Kao, Tin Mao, John F. Wright, Katherine High, Per Lindell, Peter French, David Suhy

6:00 PM

78: Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release of Infectious Virus

David R. McGivern, Takahiro Masaki, LiFang Ping, Yan Yang, Paul Ingravallo, Sara Williford, Anita Y. Howe, Stanley M. Lemon

Parallel 12: NASH: Diagnosis and Treatment

Sunday, November 3

4:45 - 6:15 PM Ballroom C

MODERATORS: Silvia Sookoian, MD, PhD

Vlad Ratziu, MD

4:45 PM

79: The rs2294918 K434E PNPLA3 Polymorphism is associated with Nonalcoholic Fatty Liver and Steatohepatitis

Luca Valenti, Stefano Romeo, Benedetta M. Motta, Benedetta Del Menico, Raffaela Rametta, Giula Buonaiuto, Anna Alisi, Anna Ludovica Fracanzani, Enrico Mozzi, Benedetta Donati, Maria Antonella Burza, Paola Dongiovanni, Valerio Nobili, Silvia Fargion

5:00 PM

80: Metabiomic Signature of Human Non-Alcoholic Fatty Liver Disease Provides Insights into Potential Microbial Contribution to Disease Status

Puneet Puri, Mohammad S. Siddiqui, Carol Sargeant, Sherry L. Boyett, Larry D. White, Kalyani Daita, Faridoddin Mirshahi, Melanie White, Tommy Pacana, Vaishali Patel, Andrew R. Joyce, Masoumeh Sikaroodi, Iliana Bouneva, Richard K. Sterling, R. Todd Stravitz, Velimir A. Luketic, Robert Mohney, Jasmohan S. Bajaj, Patrick M. Gillevet, Arun J. Sanyal

5:15 PM

81:Circulating micro-RNA Profile in Nonalcoholic Fatty Liver Disease: Potential Biomarkers and its role in the modulation of the metabolic syndrome?

Carlos J. Pirola, Tomas Fernandez Gianotti, Adriana L. Burgueno, Gustavo O. Castaño, Silvia Sookoian

5:30 PM

82: Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH

Kenneth Cusi, Beverly Orsak, Romina Lomonaco, Fernando Bril, Carolina Ortiz-Lopez, Joan Hecht, Amy Webb, Fermin Tio, Celia M. Darland, Jean Hardies

5:45 PM

83: Modest Alcohol Consumption Decreases the Risk of Having Nonalcoholic Fatty Liver Disease: A MetaAnalysis of 43,175 Individuals

Silvia Sookoian, Gustavo O. Castaño, Carlos J. Pirola

6:00 PM

84: Hedgehog Pathway Targeted by Vitamin E Therapy in NASH

Cynthia D. Guy, Ayako Suzuki, Manal F. Abdelmalek, James Burchette, Anna Mae Diehl

Parallel 13: PBC, PSC and Autoimmune Disease

Sunday, November 3

4:45 - 6:15 PM Room 146BC


Giorgina Mieli-Vergani, Md, PhD

4:45 PM

85: Defining Optimal Laboratory Response Criteria in UDCA Treated Primary Biliary Cirrhosis. Results of an International Multicenter Long-term Follow-up Study

Willem J. Lammers, H. R. van Buuren, Albert Pares, Gideon M. Hirschfield, Harry L. Janssen, Teru Kumagi, Pietro Invernizzi, Pier Maria Battezzati, Annarosa Floreani, Cyriel Y. Ponsioen, Christophe Corpechot, Marlyn J. Mayo, Jayant A. Talwalkar, Andrew K. Burroughs, Frederik Nevens, Andrew L. Mason, Kris V. Kowdley, Marjolijn Leeman, Llorenc Caballeria, Palak J. Trivedi, Angela C. Cheung, Ana Lleo, Nora Cazzagon, Irene Franceschet, Kirsten Boonstra, Elisabeth MG M. de Vries, Raoul Poupon, Mohamad Imam, Giulia Pieri, Pushpjeet Kanwar, Keith D. Lindor, Bettina E. Hansen

5:00 PM

86: Validation of Alkaline Phosphatase and Bilirubin Values as a Surrogate Endpoint in Primary Biliary Cirrhosis - an International, Collaborative Study

Willem J. Lammers, H. R. van Buuren, Harry L. Janssen, Pietro Invernizzi, Pier Maria Battezzati, Annarosa Floreani, Gideon M. Hirschfield, Albert Pares, Cyriel Y. Ponsioen, Christophe Corpechot, Marlyn J. Mayo, Jayant A. Talwalkar, Andrew K. Burroughs, Frederik Nevens, Andrew L. Mason, Kris V. Kowdley, Bibi L. Bouwen, Teru Kumagi, Angela C. Cheung, Ana Lleo, Nora Cazzagon, Irene Franceschet, Palak J. Trivedi, Llorenc Caballeria, Kirsten Boonstra, Elisabeth MG M. de Vries, Raoul Poupon, Mohamad Imam, Giulia Pieri, Pushpjeet Kanwar, Keith D. Lindor, Bettina E. Hansen

5:15 PM

87: Characterization of the Intestinal Microbiome in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis

David Kevans, Andrea D. Tyler, Kristian Holm, Kristin K. Jorgensen, Morten H. Vatn, Tom H. Karlsen, Dirk Gevers, Johannes R. Hov, Mark S. Silverberg

5:30 PM

88: VAP-1 activity is elevated in PSC and modulates a4B7-dependent lymphocyte adhesion to HSEC under flow

Palak J. Trivedi, Chris J. Weston, Evaggelia Liaskou, Christopher Corbett, David H. Adams

5:45 PM

89: Chronic antigenic stimulation may predispose to the development of IgG4-related disease of bile ducts and pancreas

Lucas Maillette de Buy Wenniger, Emma L. Culver, Roger W. Chapman, Eleanor Barnes, Ulrich Beuers

6:00 PM

90: Genetic and clinical differences in primary sclerosing cholangitis patients with high IgG4

Natalie L. Berntsen, Olay Klingenberg, Kirsten M. Boberg, Tom H. Karlsen, Johannes R. Hov

Parallel 14: Predictors of Liver Transplantation Outcomes

Sunday, November 3

4:45 - 6:15 PM Room 152A

MODERATORS: Goran Klintmalm, MD, PhD

Abraham Shaked, MD, PhD

4:45 PM

91:Frailty Score Predicts Outcomes Among Liver Transplant Candidates and Recipients

Christopher J. Sonnenday, Michael Volk, Michael J. Englesbe

5:00 PM

92: The Unintended Effect of the MELD Exception Study Group (MESSAGE) Recommendations: More MELD Exceptions

Patrick G. Northup, Nicolas M. Intagliata, Neeral L. Shah, Curtis K. Argo

5:15 PM

93: Glycosylated Hemoglobin as a novel Predictor of Renal Impairment after Orthotopic Liver Transplantation

Steffen Gerbermann, Hanna E. Tonissen, Arndt Weinmann, Sandra Koch, Maria Hoppe-Lotichius, Tim Zimmermann, Jens Mittler, Peter R. Galle, Hauke Lang, Gerd Otto, Martin F. Sprinzl

5:30 PM

94: Impact of the Donor Risk Index (DRI) on Fibrosis Progression in Hepatitis C virus (HcV) Infected Liver Transplant Recipients

Chris J. Maxwell, Sameer Desale, Bhaskar Kallakury, Elizabeth Landry, Jonathan C. Julia, Jacqueline Laurin, Rohit Satoskar, Thomas Fishbein, Kirti Shetty

5:45 PM

95: Nonalcoholic steatohepatitis (NASH) is an independent predictor of portal vein thrombosis (PVT) at the time liver transplantation (LT)

Danielle Brandman, Jennifer L. Dodge, John P. Roberts, Norah Terrault

6:00 PM

96: Waitlist outcomes for hepatopulmonary syndrome: Does oxygenation matter?

David S. Goldberg, Sachin Batra, Rajasekhar Tanikella, Steven M. Kawut, Michael B. Fallon

Parallel 15: Translational and Experimental Research in Pediatric Hepatology

Sunday, November 3

4:45 - 6:15 PM Room 146A

MODERATORS: Joshua Friedman, MD, PhD

Alexander G. Miethke, MD

4:45 PM

97: Heterozygosity for deleterious mutations in Abcb4 is associated with a pro-inflammatory hepatic transcriptome predisposing neonatal mice to cholestatic liver injury

Alexandra N. Menchise, Celine S. Lages, Julia Simmons, Rebekah Karns, Kenneth D R. Setchell, Wujuan Zhang, Susanne N. Weber, Jorge A. Bezerra, Alexander G. Miethke

5:00 PM

98: Acetaminophen (APAP)-Induced Hepatotoxicity and Failure of Liver Regeneration Results from Cellular DNA Damage and Replicative Stress that is Reversed via Paracrine Signaling From Healthy Transplanted Cells and Offers New Therapeutic Mechanisms

Preeti Viswanathan, Sriram Bandi, Sanjeev Gupta

5:15 PM

99: Autophagy is induced by the bile acid norUDCA, which may be a potential therapy for alpha-1-antitrypsin deficiency

Jeffrey Teckman, Peter Fickert, Michael Trauner

5:30 PM

100: Characterizing Fructose-Induced Steatohepatitis in Zebrafish Larvae

Valerie Sapp, Leah P. Gaffney, Steven F. Eau Claire, Randolph P. Matthews

5:45 PM

101: High fat diet increases E coli proportion in the gut microbiota and promotes the development of bile duct lesions in Cftr knockout mice

Dominique Debray, Loïc Brot, Haquima El Mourabit, Véronique D. Barbu, Dominique Rainteau, Harry Sokol, Chantal Housset

6:00 PM

102: Intrahepatic bile duct regeneration in mice does not require HNF6 and RBP-J-mediated Notch signaling

Teagan J. Walter, Charles Vanderpool, Mary Kay Washington, Anna L. Means, Stacey S. Huppert

SIG Program

Sunday, November 3

4:45 - 6:45 PM Room 145

Challenges in Diagnosis and Management of Chronic Hepatitis B Virus (HBV) Infection in Endemic Countries

Sponsored by the Hepatitis B SIG

MODERATORS: Jordan J. Feld, MD

Brian J. McMahon, MD

This program will discuss the status of current programs for diagnosis and management of chronic HBV in developing countries endemic for HBV and what the challenges are.

Learning Objectives:

  • Define what we know and what gaps remain in our understanding of the epidemiology of chronic hepatitis B and Hepatocellular Carcinoma (HCC) in developing countries
  • Discuss current existing programs for diagnosis and management of HBV in different regions of the world
  • Identify challenges that need to be overcome to provide care for persons with chronic HBV
  • Describe the components of a specific action plan for management of HBV in resource-constrained regions

4:45 - 4:55 PM Introduction

Brian J. McMahon, MD and Jordan J. Feld, MD

4:55 - 5:10 PM Epidemiology of HBV and Hepatocellular Carcinoma (HCC): Strategies to Collect the Needed Data

John W. Ward, MD

5:10 - 5:25 PM Access to Treatment: Asia

Seng Gee Lim, MD

5:25 - 5:40 PM Access to Treatment: Africa

Mark R. Thursz, MD

5:40 - 5:55 PM WHO Plan for Management of Chronic HBV

Stefan Wiktor, MD

5:55 - 6:10 PM Lessons from HIV

David Thomas, MD

6:10 - 6:40 PM Panel Discussion

6:40 - 6:45 PM Conclusion

SIG Program

Sunday, November 3

4:45 - 6:45 PM Room 147

The Changing Spectrum of Bacterial Infections in Cirrhosis

Sponsored by the Acute in Chronic Liver Failure SIG

MODERATORS: Jasmohan S. Bajaj, MD

Patrick S. Kamath, MD

The overarching purpose of this program is to provide a cutting- edge and detailed understanding of recent advances and research into the impact of the changing spectrum of infections in cirrhosis. There is an immense interest in the management and prevention of infections, especially nosocomial and MDR-organism-related infections. This is evidenced by the recent publications and controversies regarding gut microbiome, continuing prophylaxis and changing strategies for management of infections in inpatient and outpatient cirrhotics. This program is distinctive because it incorporates clinical and translational science that will engender a keen debate about both clinical and research issues.

Learning Objectives:

  • Measure the impact of the changing bacteriology of infections in cirrhosis
  • Report the advances in the pathogenesis of infections
  • Investigate the measures to prevent infectious disease

4:45 - 4:50 PM Introduction

Jasmohan S. Bajaj, MD

4:50 - 5:02 PM Changing Epidemiology of Bacterial Infections in Cirrhosis: Role of MDR Organisms

Javier Fernandez, MD

5:02 - 5:12 PM Discussion

5:12 - 5:24 PM Pathophysiology of Propagation of Infections and Their Complications

Richard Moreau, MD

5:24 - 5:34 PM Discussion

5:34 - 5:46 PM Role of Gut Microbiome in the Complications of Cirrhosis and Infections

Jasmohan S. Bajaj, MD

5:46 - 5:56 PM Discussion

5:56 - 6:08 PM How Can We Prevent Nosocomial and MDR Infections? An Infectious Disease Physician's Perspective

Larry Baddour, MD

6:08 - 6:18 PM Discussion

6:18 - 6:30 PM Future Challenges and Development of New Strategies for Unmet Needs

Patrick S. Kamath, MD

6:30 - 6:40 PM Discussion

6:40 - 6:45 PM Wrap-up

SIG Program

Sunday, November 3

4:45 - 6:45 PM Room 150A

The Cell Biology of Hepatic Disease

Sponsored by the Liver Cell Biology in Hepatic Disease and Liver Fibrosis SIGs

MODERATORS: Mark A. McNiven, PhD

Natalie Torok, MD

Allan W. Wolkoff, MD

Natalia Nieto, PhD

This special interest group program has been combined by the Hepatic Cell Biology and Mechanisms of Liver Fibrosis SIGs. The program is divided into sub-sections covering basic hepatocellular processes such as membrane trafficking, cell signaling, cytoskeletal dynamics, and matrix/stromal biology. Extending from these seminal processes will be disease-oriented presentations on cholestasis, viral infection, and steatosis with a strong emphasis on hepatocellular injury as it relates to liver fibrosis. The program includes state-of-the-art talks in the field and provides a unique perspective on how cellular processes are connected during liver injury.

Learning Objectives:

  • Gain a greater understanding of basic cell biological functions of hepatic cells such as protein/lipid traffic, cytoskeletal organization, cellular polarity, and receptor signaling cascades in health and disease. Pathological changes in cellular functions can translate into modulation of trafficking, cell adhesion and matrix production leading to liver damage, cholestasis, and fibrogenic signals
  • Understand how the central processes listed above are altered and tailored to suit the highly specialized functions of the liver including regeneration, bile formation, endocytic-based filtering of the blood, secretion of essential plasma proteins, and regulation of the extracellular matrix
  • Identify how hepatocellular functions are usurped and modified during hepatic diseases such as liver fibrosis and cancer

4:45 - 4:47 PM Introduction

Session I: Membrane Traffic and Signaling in Hepatic Disease

4:47 - 5:14 PM Regulation of Hepatic Steatosis and Liver Injury by Autophagy

Mark J. Czaja, MD

5:14 - 5:41 PM Growth Factor Pathways in Development and Progression of Hepatocellular Carcinoma

George K. Michalopoulos, MD, PhD

5:41 - 5:51 PM Break

Session II: Cell Adhesion, Stromal Biology and Hepatic Fibrosis

5:51-6:18 PM Kinase Activation Pathways in Hepatic Fibrosis

Vijay Shah, MD

6:18 - 6:45 PM Cellular Mechanisms of Hepatic Fibrosis

Rebecca G. Wells, MD

Early Morning Workshops

Monday, November 4

6:45 - 7:45 AM Refer to your luncheon ticket for meeting room location.

Monday Basic Early Morning Workshops

EMW-15 Macrophage Polarization in Liver Disease

Laura E. Nagy, PhD and Costica Aloman, MD

EMW-16 Animal Models of PBC

M. Eric Gershwin, MD and Juan F. Medina, MD, PhD

EMW-17 Mechanisms of Drug-induced Liver Injury

Hartmut Jaeschke, PhD and John J. Lemasters, MD, PhD

EMW-18 Roles of Autophagy in Liver Pathophysiology

Mark J. Czaja, MD and Wen-Xing Ding, PhD

EMW-19 Inflammasome Involvement in Liver Disease

Gyongyi Szabo, MD, PhD and Wajahat Z. Mehal, MD

EMW-20 Role of MicroRNAs in Liver Disease

Joshua Friedman, MD, PhD and Kalpana Ghoshal, PhD

Monday Clinical Early Morning Workshops

EMW-21 Controversies in Management of PSC

Jayant A. Talwalkar, MD and Roger W. Chapman, MD, PhD

EMW-22 Who and How to Screen for Wilson Disease

Peter Ferenci, MD and Frederick K. Askari, MD, PhD

EMW-23 Acute on Chronic Liver Failure: An Update

K. Rajender Reddy, MD and Rajiv Jalan, MD, PhD

EMW-24 Emerging Therapies for Management of NASH

Naga P. Chalasani, MD and Vlad Ratziu, MD

EMW-25 Management of HIV/HCV Co-infection in the DAA Era

Mark S. Sulkowski, MD and Richard K. Sterling, MD, MSc

EMW-26 HCV: Management of Non-responders including DAA

Marc G. Ghany, MD and Gregory T. Everson, MD

EMW-27 Beneficial Effects of Coffee Consumption in Liver Disease

Kiran Bambha, MD and Dawn M. Torres, MD

EMW-28 Are Patients With Chronic Liver Disease At Greater Risk Of Drug-Induced Liver Injury?

Paul B. Watkins, MD and Robert J. Fontana, MD

Poster Session III

Monday, November 4

8:00 AM - 5:30 PM

Hall E

Refer to page 149 for Poster Presentations

Exhibit Hall

Monday, November 4

9:30 AM - 3:00 PM

Hall D

Plenary Session

Presidential Plenary: Scientific Advances in Hepatology

Monday, November 4

8:00 - 9:30 AM Hall E/General Session

MODERATORS: Ronald J. Sokol, MD

J. Gregory Fitz, MD

8:00 AM

103: Interleukin-33 Induces a Potent Cholangiocyte Proliferation via a Novel Paracrine Circuit

Jun Li, Pranavkumar Shivakumar, Stephanie Walters, Tatsuki Mizuochi, Reena Mourya, Kazuhiko Bessho, Jorge A. Bezerra

8:15 AM

104: Signaling via the osteopontin and high-mobility group box-1 axis drives the fibrogenic response to liver injury

Elena Arriazu, Xiaodong Ge, Tung Ming Leung, Aritz Lopategi, Yongke Lu, Naoto Kitamura, Raquel Urtasun, Neil D. Theise, Natalia Nieto

8:30 AM

105: Cell Fate Tracking Reveals Hepatocytes as the Primary Cellular Source for Hepatocellular Carcinoma

Regina Español Suñer, Xueru Mu, Christine Sempoux, Dianne H. Dapito, Frederic Lemaigre, Isabelle A. Leclercq, Robert Schwabe

8:45 AM

106: The mast cell stabilizer, cromolyn sodium, reduces bile duct ligated-induced biliary hyperplasia: a novel role for the in vivoparacrine influence of mast cells on biliary proliferation

Laura Hargrove, Lindsey Kennedy, Taylor Francis, Kyle M. Hodges, Allyson B. Graf, Yoshiyuki Ueno, John F. Greene, Heather L. Francis

9:00 AM

107: Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis

James H. Tabibian, Steven O'Hara, Patrick L. Splinter, Christy E. Trussoni, Nicholas F. LaRusso

9:15 AM

108: Innate immune signaling couples endoplasmic reticulum stress to hepatocyte apoptosis via STING and mitochondrial IRF3 interactions

Jan Petrasek, Arvin Iracheta-Vellve, Timea Csak, Karen Kodys, Evelyn A. Kurt-Jones, Katherine A. Fitzgerald, Gyongyi Szabo

AASLD Distinguished Awards

Monday, November 4

9:30 - 9:45 AM Hall E/General Session

AASLD Distinguished Achievement Award

Presented to: Roger Williams, MD

Presented by: William M. Lee, MD

AASLD Distinguished Service Award

9:45 - 10:00 AM Hall E/General Session

Presented to: Frederick J. Suchy, MD

Presented by: Urs A. Boelstetli, PhD

Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

Monday, November 4

10:00 - 10:30 AM Hall E/General Session

Acetaminophen and the Liver: Poison or Panacea?

SPEAKER: William M. Lee, MD

MODERATOR: Neil Kaplowitz, MD

Acetaminophen has been central to our understanding of durug; induced liver injury for 50 years. Despite a great deak if stydy and accryed knowledge. Clinicians are still bafflied accrued knowledge, clinicians are still baffled by the number and severity of cases of acetaminophen hepatotoxicity that occur worldwide. It is estimated that there are 400 deaths in the U.S. annually, a number that exceeds that deaths annually due to all prescription drugs combined. This lecture will focus on possible reasons for this persistent challenge and areas to explore for future remediation of the problem.

Learning Objectives:

  • Identify the mechanism of hepatotoxicity due to acetaminophen
  • Discuss the magnitude of the acetaminophen problem and possible reasons for this
  • Describe clinical signs and symptoms of acetaminophen toxicity

The Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture recognizes Dr. Zimmerman's work in toxic liver injury. A restricted fund supporting this lecture ensures hat future investigators will have a distinct platform to present their valuable work on liver toxicity at The Liver Meeting®. AASLD gratefully acknowledges Eli Lilly and Company for its generous support of this fund.

Exhibit Hall D

10:30 - 11:00 AM

Coffee Break

Advances for Practitioners

Monday, November 4

11:00 AM -12:30 PM Ballroom AB

Advances for Practitioners

MODERATOR: Mack C. Mitchell, MD

1.5 CME Credits

This session will focus on recent publications which impact the practice of Hepatology. There will be an emphasis on recognition and management of some of the common complications of cirrhosis: acute kidney injury, coagulopathy, and small hepatocellular carcinomas. The lessons learned from the study, the clinical context and its limitations will be discussed. An expert panel will answer the questions for each study. The audience will leave the session with questions such as: “Should I incorporate this information into my practice and, if so, when?”

Learning Objectives:

  • Review recent published manuscripts in clinical hepatology which impact our practice
  • Apply the lessons learned from these studies into context
  • Define how this information may immediately impact our clinical practice

11:00 - 11:10 AM Introduction

Mack C. Mitchell, MD

11:10 -11:30 AM 1. Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57:753-62.

2. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013; 62:131-7.

3. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study. J. Hepatol 2012 56:1293-8

Santiago J. Munoz, MD

11:30 -11:50 AM 1. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147-56.

2. Villa E, Camma C, Marietta M, et al Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143:1253-1260

Stephen H. Caldwell, MD

11:50 AM -12:10 PM 1. Serste T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology. 2012; 55:800-806.

2. Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤ 2 cm: Results from two Western Centers. Hepatology. 2013; 57:1426-35.

3. Tashiro H, Aikata H, Waki K, et al. Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. J Surg Oncol. 2011; 104:3-9

Jorge A. Marrero, MD

12:10 - 12:30 PM Discussion and Wrap-up

Plenary Session

Presidential Plenary: Translational Advances in Hepatology

Monday, November 4

11:00 AM - 12:30 PM Hall E/General Session

MODERATORS: Keith D. Lindor, MD

Mary E. Rinella, MD

11:00 AM

109: Integrative genomic profiling of hepatocellular adenomas identify mutational processes involved in malignant transformation

Camilla Pilati, Jean-Charles Nault, Eric Letouzé, Sandrine Imbeaud, Maxime Mallet, Anaïs Boulai, Julien Calderaro, Charles Balabaud, Benoit Terris, Valerie Paradis, Jean Yves Scoazec, Anne de Muret, Catherine Guettier, Paulette Bioulac-Sage, Fabien Calvo, Jessica Zucman-Rossi

11:15 AM

110: Thrombocytopenia in Acute Liver Failure (ALF): A Marker of Multi-Organ System Failure and Poor Prognosis

R. Todd Stravitz, Caitlyn Ellerbe, Valerie Durkalski, Adrian Reuben, William M. Lee

11:30 AM

111: High-dose corticosteroid therapy following portoenterostomy in infants with biliary atresia does not improve outcome: The multi-center, randomized, double-blind, placebo-controlled START Trial

Jorge A. Bezerra, Cathie Spino, John C. Magee, Benjamin L. Shneider, Philip Rosenthal, Kasper S. Wang, Jessi Erlichman, Barbara Haber, Paula M. Hertel, Saul J. Karpen, Nanda Kerkar, Kathleen M. Loomes, Jean P. Molleston, Karen F. Murray, Rene Romero, Kathleen B. Schwarz, Ross Shepherd, Frederick J. Suchy, Yumirle P. Turmelle, Peter F. Whitington, Jeffrey Moore, Averell H. Sherker, Patricia R. Robuck, Ronald J. Sokol

11:45 AM

112: Beta-blockers do not impact negatively on survival rates in cirrhotic patients with diuretic resistant ascites. A Danish nationwide population based study

Ulrich C. Bang, Thomas Benfield, Lars Hyldstrup, Jens-Erik B. Jensen, Flemming Bendtsen

12:00 PM

113: The Rising Burden of Herbal and Dietary Supplement Induced Hepatotoxicity in the U. S. A

Victor J. Navarro, Huiman X. Barnhart, Herbert L. Bonkovsky, Timothy J. Davern, Robert J. Fontana, Lafaine Grant, Jay H. Hoofnagle, K. Rajender Reddy, Leonard B. Seeff, Jose Serrano, Averell H. Sherker, Andrew Stolz, Jayant A. Talwalkar, Maricruz Vega, Raj Vuppalanchi

12:15 PM

114: Serum keratin fragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease (NAFLD): Results from the TONIC trial

Ajay K. Jain, Ross B. Deppe, Katherine P. Yates, Megan Comerford, Howard C. Masuoka, Jean P. Molleston, Jeffrey B. Schwimmer, Joel E. Lavine, Elizabeth M. Brunt, James Tonascia, David E. Kleiner, Naga P. Chalasani

Professional Development Workshop

Monday, November 4

11:45 AM -1:15 PM Renaissance Hotel, Congressional Hall B

Professional Development Workshop

MODERATORS: Gyongyi Szabo, MD PhD

Claudia O. Zein, MD

Simona Rossi, MD

What does “success” mean to you now and how has that been changing? In what ways would you like to increase your influence? Gaining clarity in these areas greatly assists you to make wise decisions about your priorities and to achieve the results you want in your work and life. This session offers a number of lenses and strategies that will help you manage tensions between your career development and organizational needs and to achieve resiliency in the face of constant change.

Learning Objectives:

  • Clarify what “power,” “success” and “influence” means to you
  • Make more strategic choices regarding their commitments
  • Mangage tensions between career development and organizational needs
  • Speak effectively about their goals and accomplishments
  • Apply insights into gender-related differences in these skill areas

11:45 AM -1:15 PM How is Your Vision of Success and Influence Changing? Developing Strategies that Work for You

Janet Bickel, MA

American College of Physicians (ACP) Lecture

Monday, November 4

12:30 -1:30 PM 152A

ACP Lecture

This lecture is intended to introduce the concept of high value care to the membership of AASLD. The high value care initiative was started by the American College of Physicians (ACP) in 2010 to increase awareness of unsustainable national health care costs and to help practicing physicians simultaneously reduce waste and improve the quality of care they provide to patients. The lecture will introduce a novel case based curriculum to encourage open discussion of these important issues. The content will be a mixture of clinical and basic knowledge.

Learning Objectives:

  • Understand physician driven sources of excessive healthcare costs
  • Define healthcare value as the process of balancing clinical benefit with harms and costs
  • Identify care that provides no benefit and may be harmful
  • Overcome some of the barriers to high value care (patient expectations, malpractice concerns, patient access, pharmaceutical marketing)

12:30 - 1:30 PM Wasting the Buck Stops Here: How Physicians Can Reduce Healthcare Spending and Improve Outcomes

Daisy Smith, MD

Exhibit Hall D

1:30 - 2:00 PM

Snack Break

Global Forum

Monday, November 4

2:00 - 4:00 PM Room 151

Fatty Liver Disease - Alcoholic and Nutritional

MODERATORS: J. Gregory Fitz, MD

Adrian M. Di Bisceglie, MD

2 CME Credits

The global forum focuses on the world-wide public health epidemic of liver diseases caused by excessive alcohol use or obesity and the metabolic syndrome. The aim of this progream is to develop a discussion on this topic among the five major regions of the world, North America, Europe, Latin America, Asia and Africa. The speakers represent each region and discuss important issues and/or barriers related to the epidemiology, diagnosis and management of alcoholic and non-alcoholic fatty liver diseases. The discussion will address the most important public health problems regarding fatty liver diseases in each of these regions.

2:00 - 2:05 PM Introduction

J. Gregory Fitz, MD

2:05 - 2:20 PM State-of-the-Art: Fatty Liver Disease

Gyongyi Szabo, MD, PhD

2:20 - 2:35 PM Challenges in North America

Gary J. Murray, PhD

2:35 - 2:50 PM Challenges in Europe

Philippe Mathurin, MD, PhD

2:50 - 3:05 PM Challenges in Latin America

Nahum Méndez-Sanchéz, MD, PhD

3:05 - 3:20 PM Challenges in Asia

Vincent W. Wong, MD

3:20 - 3:35 PM Challenges in Africa

Magdy El-Serafy, MD

3:35 - 4:00 PM Discussion

Late-Breaking Abstract Session

Monday, November 4

2:45 - 4:30 PM Hall E/General Session

Presidential Address: J. Gregory Fitz, MD


Donald M. Jensen, MD

Emerging Trends Symposium

Monday, November 4

3:00 - 4:30 PM Room 147

Hepatitis E

MODERATOR: Kenneth E. Sherman, MD, PhD

1.5 CME Credits

Hepatitis E virus (HEV) has long been recognized as a cause of acute infectious hepatitis in in parts of the world where fecal contamination of water and food supplies is common. However, there is increasing evidence that HEV is a common and frequently unrecognized pathogen in the U.S. and Europe as well. Patients with chronic liver disease and other immunosuppressed populations may be at particular risk of acute and chronic liver injury.

Learning Objectives:

  • Understand the virology of HEV and the limitations of current diagnostic modalities
  • Apply knowledge of the epidemiology of HEV in the U.S. and elsewhere
  • Identify unique clinical issues that HEV presents in patients with chronic liver disease and in immunosuppressed hosts
  • Discuss the activity, efficacy and availability of vaccines to prevent HEV infection

3:00 - 3:25 PM HEV Virology and Diagnosis

Mohamed Tarek M. Shata, MD, PhD

3:25 - 3:50 PM HEV Epidemiology in the U.S. and Elsewhere

Mark H. Kuniholm, PhD

3:50 - 4:10 PM HEV in Immunosuppressed Populations and those with Chronic Liver Disease

Kenneth E. Sherman, MD, PhD

4:10 - 4:30 PM HEV Vaccination-Lost Opportunities

James W. Shih, PhD

Parallel Session

Parallel 16: Cholangiocyte Biology

Monday, November 4

3:00 - 4:30 PM Room 150B

MODERATORS: Andrew P. Feranchak, MD

Rebecca G. Wells, MD

3:00 PM

115: Double knockout of secretin and secretin receptor exacerbates biliary damage and decreases biliary proliferation and ductal secretion during extrahepatic cholestasis: protective role of bicarbonate secretion during biliary disorders

Shannon S. Glaser, Fanyin Meng, Heather L. Francis, Julie Venter, Laura Hargrove, Holly A. Standeford, Syeda H. Afroze, Paolo Onori, Kelly McDaniel, Micheleine Guerrier, Eugenio Gaudio, Gianfranco Alpini

3:15 PM

116: Knockout of the histidine decarboxylase (HDC) gene reduces biliary hyperplasia in cholestatic bile duct ligated (BDL) mice

Laura Hargrove, Hiroshi Ohtsu, Taylor Francis, Yoshiyuki Ueno, Lindsey Kennedy, Kyle M. Hodges, Allyson B. Graf, John F. Greene, Heather L. Francis

3:30 PM

117: Epigenetic regulation of definitive endoderm markers in biliary-committed progenitor cells during cholestatic liver injury

Kelly McDaniel, Julie Venter, Heather L. Francis, Yuyan Han, Taylor Francis, Jia-ming Lai, Li Huang, Debolina Ray, Shannon S. Glaser, Gianfranco Alpini, Fanyin Meng

3:45 PM

118: MicroRNAs Dysregulation Induces HDAC6 Overexpression in Cholangiocarcinoma

Sergio A. Gradilone, Brynn N. Radtke, Gabriella Gajdos B, Christy E. Trussoni, Justin L. Mott, Nicholas F. LaRusso

4:00 PM

119: Cholangiocytes present antigens to NKT cells

Elisabeth Schrumpf, Tom H. Karlsen, Sebastian Zeissig, Mark A. Exley, Richard S. Blumberg, Espen Melum

4:15 PM

120: Development and characterization of an extrahepatic cholangiocyte culture system from the rat common bile duct

Julie Venter, Laura Hargrove, Sharon DeMorrow, Kelly McDaniel, Micheleine Guerrier, Marco Marzioni, Gabriel A. Frampton, Holly A. Standeford, Eugenio Gaudio, Paolo Onori, Debolina Ray, Shannon S. Glaser, Fanyin Meng, Heather L. Francis, Gianfranco Alpini

Parallel 17: Clinical Advances in Pediatric Hepatology

Monday, November 4

3:00 - 4:30 PM Room 146A

MODERATORS: Kathleen B. Schwarz, MD

Patrick J. McKiernan, BSc, FRCP

3:00 PM

121: Genetic polymorphisms of IL28B gene and spontaneous clearance of hepatitis C virus in children

Giuseppe Indolfi, Giusi Mangone, Pier Luigi Calvo, Elisa Bartolini, Marta Regoli, Daniele Serranti, Carmelina Calitri, Pier-Angelo Tovo, Maurizio de Martino, Chiara Azzari, Massimo Resti

3:15 PM

122: Expression of interferon-stimulated genes (IGS) in the liver - role for predicting response to antiviral therapy in chronic hepatitis B infection?

Ivana Carey, Matthew J. Bruce, Mary Horner, Kate Childs, Deepak Joshi, Sanjay Bansal, Diego Vergani, Giorgina Mieli-Vergani

3:30 PM

123: Dynamics of Allograft Fibrosis in Pediatric Liver Transplantation

Carla Venturi, Christine Sempoux, Etienne M. Sokal, Xavier Stephenne, Christophe Bourdeaux, Raymond Reding

3:45 PM

124: Serum microRNAs as Novel Non-invasive Diagnostic Biomarkers of Liver Disease in Children with Cystic Fibrosis

Naomi L. Cook, Tamara N. Pereira, Peter J. Lewindon, Ross Shepherd, Grant A. Ramm

4:00 PM

125: Identifying Frequency Of Inherited Metabolic Disorders In Patients With Infantile Liver Disease

Zoe Gray, Kirsten McKay, Carla Lloyd, Jane Hartley, Fiona MacDonald, Christian J. Hendriksz, Paul Gissen, Deirdre A. Kelly

4.15 PM

126: Ascitic fluid infection in acute and chronic liver disease in children: Evaluation, comparative analysis and outcomes

Surender K. Yachha, Rohan Malik, Rishi Bolia, Anshu Srivastava, Ujjal Poddar

Parallel 18: Complications of Cirrhosis

Monday, November 4

3:00 - 4:30 PM Ballroom AB

MODERATORS: Juan Carlos Garcia-Pagan, MD

Theo Heller, MD

3:00 PM

127: Portal vein thrombosis (PVT) in compensated cirrhosis: A prospective cohort study on 898 patients

Filipe G. Nery, Cendrine Chaffaut, Bertrand Condat, Emmanuelle de Raucourt, Larbi Boudaoud, Pierre-Emmanuel Rautou, Aurelie Plessier, Dominique Roulot, Jean Claude Trinchet, Dominique Valla, Sylvie Chevret

3:15 PM

128: Acute kidney injury (AKI) in patients with Acute on Chronic Liver failure (ACLF) is different from patients with cirrhosis

Rakhi Maiwall, Suman Kumar, Chitranshu Vashishtha, Manoj Kumar, Hitendra K. Garg, Sumanlata Nayak, Sunil Taneja, Bhaskar Thakur, Shiv K. Sarin

3:30 PM

129: Diagnostic test accuracy of vWF for hepatopulmonary syndrome in patients with liver cirrhosis

Thomas Horvatits, Andreas Drolz, Arnulf Ferlitsch, Christian Muller, Peter Schenk, Valentin Fuhrmann

3:45 PM

130: Stratification based on acute on chronic liver failure (ACLF) has greater prognostic accuracy than stratification based on creatinine, Acute Kidney Injury (AKI), Encephalopathy or Child-Pugh Score. Prognostic relevance of 48 hour post-enrolment ACLF Stratification

Paolo Angeli, Pere Gines, Salvatore Piano, Elisabet Garcia, Filippo Morando, Ezequiel Rodriguez, Xavier Ariza, Elisabetta Gola, Elsa Sola, Monica Guevara, Richard Moreau, Rajiv Jalan, Juan Cordoba, Marco Pavesi, Francois Durand, Thierry Gustot, Faouzi Saliba, Marco Domenicali, Alexander L. Gerbes, Julia Wendon, Carlo Alessandria, Wim Laleman, Stefan Zeuzem, Jonel Trebicka, Mauro Bernardi, Vicente Arroyo

4:00 PM

131: Predicting Presence of Clinically Significant Hepatic Involvement in Hereditary Hemorrhagic Telangiectasia using a Simple Clinical Scoring Index

Siddharth Singh, Karen L. Swanson, Matthew Hathcock, Walter K. Kremers, John Pallanch, Michael J. Krowka, Patrick S. Kamath

4.15 PM

132: The Cirrhosis Dysbiosis Ratio Provides Insight into Gut Microbiome Changes Across the Spectrum of Cirrhosis: A Prospective Study of 250 Patients

Jasmohan S. Bajaj, Phillip Hylemon, Douglas M. Heuman, Arun J. Sanyal, Patrick M. Gillevet

Parallel 19: HBV Basic Virology

Monday, November 4

3:00 - 4:30 PM Room 145

MODERATORS: Thomas I. Michalak, MD, PhD

Kyong-Mi Chang, MD

3:00 PM

133: Interferons Induce Degradation Of HBV CccDNA

Yuchen Xia, Julie Lucifora, Ke Zhang, Xiaoming Cheng, Daniela Stadler, Florian Reisinger, Martin Feuerherd, Zuzanna Makowska, Daniel Hartmann, Wolfgang E. Thasler, Markus H. Heim, Mathias Heikenwalder, Ulrike Protzer

3:15 PM

134: Early and late changes in gene expression profiles following infection with hepatitis B or C virus in human hepatocyte chimeric mice

C. Nelson Hayes, Sakura Akamatsu, Masataka Tsuge, Daiki Miki, Nobuhiko Hiraga, Hiromi Abe, Michio Imamura, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama

3:30 PM

135: Baseline liver gene expression profile associated with therapy response in chronic hepatitis B patients treated with peginterferon and adefovir

Louis Jansen, Annikki de Niet, Zuzanna Makowska, Michael T. Dill, Karel A. van Dort, Bart Takkenberg, Markus H. Heim, Neeltje A. Kootstra, Hendrik W. Reesink

3:45 PM

136: The nuclear function of Hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes

Marion Gruffaz, Barbara Testoni, Souphalone Luangsay, Floriane Fusil, Ait-Goughoulte Malika, Jimmy Mancip, Marie-Anne Petit, Hassan Javanbakht, Francois-Loic Cosset, Fabien Zoulim, David Durantel

4:00 PM

137: Hepatitis B virus (HBV) core promoter (CP) mutations and AKT1(v-Akt murine thymona viral oncogene homolog 1) coactivation may be associated with hepatocellular carcinoma (HCC) prognosis

Yuehua Huang, Lin Gu, Xiaohui Huang

4.15 PM

138: HAPs hepatitis B virus (HBV) capsid inhibitors block core protein interaction with the viral minichromosome and host cell genes and affect cccDNA transcription and stability

Laura Belloni, Lichun Li, Gianna Aurora Palumbo, Srinivas Reddy Chirapu, Ludovica Calvo, Mg Finn, Uri Lopatin, Adam Zlotnick, Massimo Levrero

Parallel 20: HCV: Diagnosis and Natural History

Monday, November 4

3:00 - 4:30 PM Ballroom C

MODERATORS: Natalie H. Bzowej, MD, PhD

Timothy R. Morgan, MD

3:00 PM

139: Acute Hepatitis C Infection is Associated with an Increase in Circulating microRNA-122

Ramy El-Diwany, Kimberly Page, Stuart Ray, Andrea Cox, David L. Thomas, Ashwin Balagopal

3:15 PM

140: Pre-treatment levels of serum IFN-γ3 more accurately predict sustained virological response by pegylated interferon/ribavirin therapy than IL28B genotyping in chronic hepatitis C patients

Yoshihiko Aoki, Kazumoto Murata, Masaya Sugiyama, Tatsuji Kimura, Tsutomu Takeda, Sachiyo Yoshio, Masaaki Korenaga, Masatoshi Imamura, Tatsuya Kanto, Naohiko Masaki, Masashi Mizokami

3:30 PM

141: Diagnostic accuracy of liver stiffness (FibroScan®) in patients with chronic viral hepatitis: results of a large USA cohort

Nezam H. Afdhal, Bruce R. Bacon, Keyur Patel, Eric Lawitz, Stuart C. Gordon, David R. Nelson, Tracy L. Challies, Imad Nasser, Lee jen Wei, John G. McHutchison

3:45 PM

142: Evaluation of liver disease progression in the German HCV (1b)-contaminated anti-D cohort at 35 years after infection

Manfred Wiese, Janett Fischer, Micha Loebermann, Uwe Göbel, Kurt Gruengreiff, Wolfgang Güthoff, Ulrike Kullig, Franziska Richter, Ingolf Schiefke, Hannelore Tenckhoff, Alexander Zipprich, Thomas Berg, Tobias Mueller

4.00 PM

143: The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response

Adriaan J. van der Meer, Jordan J. Feld, Harald Hofer, Piero L. Almasio, Vincenza Calvaruso, Conrado M. Fernandez-Rodriguez, Soo Aleman, Nathalie Ganne-Carrie, Roberta D'Ambrosio, Stanislas Pol, Maria Trapero-Marugan, Ricardo Moreno-Otero, Vincent Mallet, Rolf W. Hultcrantz, Ola Weiland, Karoline Rutter, Vito Di Marco, Sonia Alonso, Savino Bruno, Massimo Colombo, Robert J. de Knegt, Bart J. Veldt, Bettina E. Hansen, Harry L. Janssen

4:15 PM

144: Sexual function is impaired in men and women with chronic hepatitis C

Julien Vergniol, Genevieve Hou, Juliette Foucher, Florence Chenus, Faberes Carole, Faiza Chermak, Aude Lafourniere, Noui Souakri, Victor de Ledinghen

Parallel 21: Inflammation and Fibrosis

Monday, November 4

3:00 - 4:30 PM Room 150A

MODERATORS: Natalie Torok, MD

Robert Schwabe, MD

3:00 PM

145: HIV-infection of Kupffer cells results in a dysregulated response to LPS despite effective AntiRetroviral Therapy

Arevik Mosoian, Feng Hong, Yedidya Saiman, Adeeb Rahman, Andrea D. Branch, Sasan Roayaie, Sander Florman, Francesc Cunyat, Mario Stevenson, Meena Bansal

3:15 PM

146: HCV is taken up by human liver sinusoidal endothelial cells (LSECs) and triggers IFN Type I and III (lambda) production and autocrine/paracrine signaling that inhibits HCV replication

Silvia Giugliano, Lucy Golden-Mason, Evgenia Dobrinskikh, Amy E. Stone, Alejandro Soto-Gutierrez, Michael Gale, Vijay Shah, Hugo R. Rosen

3:30 PM

147: Hepatic sdf-1 (CXCL12) acts downstream of VEGF to recruit liver sinusoidal endothelial cell progenitor cells from the bone marrow in liver regeneration

Laurie D. Deleve, Xiandong Wang, Lei Wang, William A. Gaarde

3:45 PM

148: Hepatic Stellate Cells Orchestrate Clearance of Dead Hepatocytes from the Liver after Acute Injury in a Hypoxia-inducible Factor-1α-dependent Manner

Bryan Copple, Aaron Pace, Akie J. Mochizuki, Keara Towery, James P. Luyendyk

4:00 PM

149: Macrophage autophagy protects from liver fibrosis

Jasper Lodder, Marie-Noële Chobert, Sophie Lotersztajn, Fatima Teixeira-Clerc

4:15 PM

150: The liver-derived plasma protein histidine-rich glycoprotein promotes chronic liver injury and fibrosis by polarizing hepatic macrophages towards the inflammatory M1 phenotype

Matthias Bartneck, Viktor Fech, Josef Ehling, Xiao Wei, Klaudia Warzecha, Kanishka Hittatiya, Nikolaus Gassler, Twan Lammers, Willi Jahnen-Dechent, Christian Trautwein, Frank Tacke

Parallel 22: Signaling in Hepatotoxicity

Monday, November 4

3:00 - 4:30 PM Room 152A

MODERATORS: Craig J. McClain, MD

Urs A. Boelsterli, PhD

3:00 PM

151: The Ryanodine Receptor is Required for Inflammasome Activation, Hepatitis and Fibrosis

Md Kaimul Ahsan, Wajahat Z. Mehal

3:15 PM

152: LPS-stimulated stellate cells augment acetaminophen-induced hepatocyte injury: Role for IFN-β

Chandrashekhar R. Gandhi

3:30 PM

153: Grb2-associated binder 1 docking protein is crucial for mortality in a mouse model of acute liver failure

Kunimaro Furuta, Yuichi Yoshida, Takashi Kizu, Satoshi Ogura, Mayumi Egawa, Norihiro Chatani, Mina Hamano, Hisao Ezaki, Yoshihiro Kamada, Shinichi Kiso, Tetsuo Takehara

3:45 PM

154: Ethanol-inducible CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis and apoptosis

Mohamed A. Abdelmegeed, Atrayee Banerjee, Sehwan Jang, Seong-Ho Yoo, Frank Gonzalez, Ali Keshavarzian, Byoung-Joon Song

4:00 PM

155: Deoxycholic Acid Triggers Primary Rat Hepatocyte Apoptosis in a Dose-Dependent Manner by Hampering Caspase-2/NF-κB-associated Activation of miRNA-21

Pedro M. Rodrigues, Marta B. Afonso, Duarte M. Ferreira, Pedro M. Borralho, Cecilia M. Rodrigues, Rui E. Castro

4:15 PM

156: Activation of protein kinase C delta protects against bile acid induced apoptosis by suppression of a pro-apoptotic JNK/BIM pathway

Cynthia R. Webster, Mohammed S. Anwer

HCV Symposium

Monday, November 4

4:45 - 6:15 PM Hall E/General Session

Integrating New Therapies for the Treatment of Chronic Hepatitis C

MODERATORS: Michael W. Fried, MD

Nancy Reau, MD

The positive impact of HCV treatment on morbidity and mortality remains underappreciated, as evidenced by the recent proposed report of the USPSTF. This program will emphasize the latest data on improved clinical outcomes and also highlight the latest antiviral therapies that continue to increase the rates of sustained virological response. Combined, this clinical information will provide important motivation for healthcare providers to discuss HCV treatment options with their patients. It will also provide them with the knowledge to select the best individual options from a variety of available treatment options expected to be approved over the next 6-12 months.

Learning Objectives:

  • Identify the impact of HCV therapy on morbidity and mortality
  • Describe the foundation for all oral regimens
  • Explain the strengths and limitations of all-oral regimens under investigation
  • Develop a rational approach to choosing treatment regimens as multiple agents become available

4:45 - 5:00 PM Effectiveness of HCV Therapy for Improving Health Outcomes

Harry L. Janssen, MD, PhD

5:00 - 5:15 PM Review of Registration Trials of DAAs

Norah Terrault, MD

5:15 - 5:30 PM New Phase II Data from All-Oral Regimens

Fred Poordad, MD

5:30 - 5:45 PM Responsible Use of New DAAs in 2014 and Beyond

David R. Nelson, MD

5:45 - 6:15 PM Panel Discussion

Parallel Session

Parallel 23: Cholesterol and Bile Acid Metabolism

Monday, November 4

4:45 - 6:15 PM Room 150B

MODERATORS: Saul J. Karpen, MD, PhD

Gianfranco Alpini, PhD

4:45 PM

157: A novel phosphospecific RXRα Ser260 antibody uncovers new inflammation-associated cytoplasmic and submembrane localizations for the essential nuclear receptor RXRα

Hong Tang, Zhining Den, Astrid Kosters, Daniel A. Moore, Saul J. Karpen

5:00 PM

158: Uncovering a novel regulation of Bcl2 in bile acid homeostasis and cholestatic liver fibrosis

Yuxia Zhang, Hiroyuki Tsuchiya, Rana Smalling, James Cox, Don Delker, Curt H. Hagedorn, Li Wang

5:15 PM

159: Fibroblast Growth Factor 15 is Critical for Liver Regeneration after Partial Hepatectomy in Mice

Bo Kong, Jiansheng Huang, Yan Zhu, Guodong Li, Jessica A. Williams, Steven H. Shen, Lauren M. Aleksunes, Jason R. Richardson, Udayan Apte, David A. Rudnick, Grace L. Guo

5:30 PM

160: Effect of small bowel bacterial overgrowth on hepatobiliary transporter expression and bile composition in a jejunal self-filling blind loop model in mouse

Qingqing Wang, Vijay Saxena, Bin Wang, Lili Miles, Jaimie D. Nathan

5:45 PM

161: A genetic variant mimicking the effect of ezetimibe associates with increased risk of symptomatic gallstone disease

Bo K. Lauridsen, Stefan Stender, Ruth Frikke-Schmidt, B0rge G. Nordestgaard, Anne Tybjaerg-Hansen

6:00 PM

162: Ileocecal resection (ICR) in patients with Crohn's disease is associated with lower FGF19 and higher 7α-OH-cholesterol levels in comparison to ulcerative colitis

Dana Friedrich, Dieter Luetjohann, Frank Lammert, Christoph Reichel

Parallel 24: Diagnosis of Liver Tumors

Monday, November 4

4:45 - 6:15 PM Room 147

MODERATORS: Paul J. Thuluvath, MD, FRCP

Alex Befeler, MD

4:45 PM

163: B-mode Ultrasonography Versus Contrast enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial

Masatoshi Kudo, Kazuomi Ueshima, Yukio Osaki, Masashi Hirooka, Yasuharu Imai, Kazunobu Aso, Kazushi Numata, Masao Ichinose, Takashi Kumada, Namiki Izumi, Yasukiyo Sumino, Kouhei Akazawa

5:00 PM

164: Clinical Usefulness of Computed Tomography Volumetry in Estimating a Liver Mass in Surgical Subjects with Hepatic Steatosis

Yeonjung Ha, Ju Hyun Shim, Han Chu Lee, Kang Mo Kim, Young-Suk Lim, Dong Jin Suh

5:15 PM

165: Diagnostic accuracy of contrast-enhanced ultrasonography with perfluorobutane in macroscopic classification and histological differentiation of nodular hepatocellular carcinoma

Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Takanori Ito

5:30 PM

166: The use of contrast-enhanced ultrasonography for the distinction between focal nodular hyperplasia and hepatocellular adenoma

Mirelle Bröker, Pavel Taimr, Bettina E. Hansen, Robert A. de Man, Jan Uzermans

5:45 PM

167: Gadoxetic Acid-Enhanced MRI is Superior to 4-Phase CT for the Accurate Staging of Early-Stage Hepatocellular Carcinoma

Hyung-Don Kim, Jihyun An, Gi Ae Kim, Dong Jin Suh, Young-Suk Lim

6:00 PM

168: Sensitivity of MRI for Detecting Hepatocellular Carcinoma After Locoregional Therapy Prior to Liver Transplant

Jesse M. Civan, David Becker-Weidman, She-Yan Wong, Flavius Guglielmo, Steven K. Herrine, Donald G. Mitchell

Parallel 25: Diagnosis, Prognosis, and Treatment of Varices

Monday, November 4

4:45 - 6:15 PM Ballroom AB

MODERATORS: Juan G. Abraldes, MD

Scott W. Biggins, MD

4:45 PM

169: Active bleeding at endoscopy is not a prognostic factor in Child-Pugh B patients with variceal bleeding

Dominique Thabut, Marika Rudler, Nina Dib, Nicolas Carbonell, Philippe Mathurin, Faouzi Saliba, Alain Mallet, Julien Massard, Brigitte Bernard-Chabert, Frederic Oberti, Christophe Bureau

5:00 PM

170: Early TIPS in patients with acute variceal bleeding: an external validation

Marika Rudler, Philippe Cluzel, Nadjib Hammoudi, Hedi Benosman, Thierry Poynard, Dominique Thabut

5:15 PM

171: Thrombelastography decreases hemoderivates requirement before invasive procedures in cirrhotic patients with coagulation disorders. A randomized controlled trial

Marcello Bianchini, Lesley De Pietri, Tommaso Di Maira, Nicola De Maria, Bruno Begliomini, Giorgio Enrico Gerunda, Erica Villa

5:30 PM

172: Spleen Stiffness Measurement for the Detection of Esophageal Varices: Systematic Review and Metaanalysis of Diagnostic Accuracy

Siddharth Singh, John Eaton, M. Hassan Murad, Hironori Tanaka, Hiroko Iijima, Jayant A. Talwalkar

5:45 PM

173: Statins are Associated with a Decreased Risk of Variceal Bleeding in Compensated Cirrhosis

Eric S. Orman, Christopher Martin, Michael D. Kappelman, Paul H. Hayashi, Millie D. Long

6:00 PM

174: A prospective, double-blind, randomized placebo-controlled trial of carvedilol for early primary prophylaxis of esophageal varices in cirrhosis

Ankit Bhardwaj, Chandan K. Kedarisetty, Manoj Kumar, Shiv K. Sarin

Parallel 26: Experimental Portal Hypertension

Monday, November 4

4:45 - 6:15 PM Room 150A

MODERATORS: Hendrik Reynaert, MD

Yasuko Iwakiri, PhD

4:45 PM

175: Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Len D. Verbeke, Ricard Farre, Jonel Trebicka, Mina Komuta, Tania Roskams, Sabine Klein, Ingrid Vander Elst, Petra Windmolders, Tim Vanuytsel, Frederik Nevens, Wim Laleman

5:00 PM

176: Metformin reduces hepatic resistance and portal pressure in CCl4 and BDL cirrhotic rats

Dinesh M. Tripathi, Eva Erice, Jordi Gracia-Sancho, Hector Garcia-Caldero, Shiv K. Sarin, Jaime Bosch, Juan Carlos Garcia-Pagan

5:15 PM

177: Vasopressin 1a (V1a) Receptor Partial Agonism Increases Sodium Excretion And Reduces Portal Hypertension And Ascites In Cirrhotic Rats

Guillermo Fernández-Varo, Denise Oro, Edward Cable, Vedrana Reichenbach, Silvia Carvajal, Bernadino Gonzalez de la Presa, Kazimierz Wisniewski, Pere Gines, Geoffrey Harris, Wladimiro Jimenez

5:30 PM

178: Key role of the enzyme chymase in the hepatic production of angiotensin II and in the development of liver cirrhosis: animal and human data

Giovanni Sansoe, Manuela Aragno, Raffaella Mastrocola, Giulio Mengozzi, Claudia Paternostro, Maurizio Parola

5:45 PM

179: The mechanisms of arterial thinning observed in cirrhotic rats with portal hypertension

Hui-Chun Huang, Keitaro Tashiro, Teruo Utsumi, Yasuko Iwakiri

6:00 PM

180: Intrahepatic Microvascular Thrombosis contributes to Fibrogenesis and Portal Hypertension in Congestive Hepatopathy

Douglas A. Simonetto, Hui-yin Yang, Thiago de Assuncao, Shuchong Pan, Robert Simari, Vijay Shah

Parallel 27: Genetic Liver Disease

Monday, November 4

4:45 - 6:15 PM Room 152B


Jeffrey Teckman, MD

4:45 PM

181: The rate of disappearance of intracellular α-1-antitrypsin correlates with liver disease severity in iPSc- derived hepatocytes generated from PIZZ α-1-antitrypsin deficiency patients

Edgar N. Tafaleng, Bing Han, Pamela D. Hale, Souvik Chakraborty, Alejandro Soto-Gutierrez, Carol Feghali-Bostwick, Darrell Kotton, Masaki Nagaya, Stephen A. Duncan, Donna B. Stolz, Stephen Strom, Jayanta Roy-Chowdhury, David H. Perlmutter, Ira J. Fox

5:00 PM

182: Administration of an iron-deficient diet attenuates diet-induced hepatic steatosis in HFE-associated nonalcoholic fatty liver disease using Hfe-/-mice

Ashley S. Wilkinson, Kim Bridle, Laurence Britton, Lesley Jaskowski, Linda M. Fletcher, V Nathan Subramaniam, Darrell H. Crawford

5:15 PM

183: Iron activation of hepcidin in hemojuvelin knockout mice preferentially targets splenic but not intestinal ferroportin

Konstantinos Gkouvatsos, Carine Fillebeen, John Wagner, Alina Daba, Giada Sebastiani, Kostas Pantopoulos

5:30 PM

184: Open label, phase-II clinical study, to evaluate the efficacy of lanreotide 90mg in symptomatic polycystic liver disease, including dose escalation at month 6 in non-responders

Frederik J. Temmerman, Thien Anh Ho, Ragna Vanslembrouck, Walter Coudyzer, Vincent De Ruyter, Jos van Pelt, Bert Bammens, Yves Pirson, Frederik Nevens

5:45 PM

185: Relapse of porphyria cutanea tarda after achieving remission with phlebotomy or low dose hydroxychloroquine

Ashwani K. Singal, Eric Gou, Marisol Albuerne, Csilla Kormos Hallberg, Karl E. Anderson

6:00 PM

186: Wilson's disease: effects of gestational methyl group supplementation on global DNA methylation and gene expression in fetal mouse liver

Valentina Medici, Noreene Shibata, Kusum K. Kharbanda, Mohammad S. Islam, Charles H. Halsted, Janine M. LaSalle

Parallel 28: HBV Natural History and Long Term Outcomes

Monday, November 4

4:45 - 6:15 PM Room 145

MODERATORS: Mindie H. Nguyen, MD

Marc G. Ghany, MD

4:45 PM

187: Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 30 year Follow-up Study and Response to a Booster Dose

Michael Bruce, Dana J. Bruden, Debby Hurlburt, Carolyn Zanis, Gail C. Thompson, Lisa D. Rea, Michele Toomey, Lisa J. Townshend-Bulson, Karen Rudolph, Lisa Bulkow, Philip Spradling, Richard Baum, Thomas W. Hennessy, Brian J. McMahon

5:00 PM

188: Reduction in eGFR in patients with chronic hepatitis B. An analysis of the Italian Master-B cohort

Giuseppina Brancaccio, Alessandra Nardi, Salvatore Madonia, Massimo Fasano, Pietro Andreone, Marco Massari, Gianluca Svegliati Baroni, Barbara Coco, Alfredo Marzano, Enzo Petrelli, Gioacchino Angarano, Caius Gavrila, Giovanni B. Gaeta

5:15 PM

189: Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - An interim report of C-TEAM study

Tung-Hung Su, Tsung-Hui Hu, Chun-Che Lin, Cheng-Yuan Peng, Wan-Long Chuang, Chi-Yi Chen, Chia-Chi Wang, Rong-Nan Chien, Yi-Hsiang Huang, Chih-Lin Lin, Sheng-Shun Yang, Yi-Wen Huang, Shih-Jer Hsu, Horng-Yuan Wang, Lein-Ray Mo, Bair Ming-jong, Cheng-Chao Liang, Tai-Chung Tseng, Chi-Ling Chen, Yung-Chao Lei, Jia-Horng Kao

5:30 PM

190: Risk and risk factors of hepatocellular carcinoma (HCC) in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)

George V. Papatheodoridis, George N. Dalekos, Cihan Yurdaydin, Ioannis Goulis, Pauline Arends, Maria Buti, Vana Sypsa, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskin, Savvoula Savvidou, Bettina E. Hansen, Christos Papaioannou, Kostas Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L. Janssen, Pietro Lampertico

5:45 PM

191: Immune correlates of chronic hepatitis B phenotypes in North America: Results from the Hepatitis B Research Network (HBRN)

Jang-June Park, David K. Wong, Abdus S. Wahed, William M. Lee, Jordan J. Feld, Norah Terrault, Mandana Khalili, Kris V. Kowdley, Daryl Lau, Richard K. Sterling, W. Ray Kim, Coleman Smith, Robert L. Carithers, Danielle L. Levine, James Keith, Mary E. Valiga, Anna S. Lok, Kyong-Mi Chang

6:00 PM

192: Hepatitis B Virus (HBV) Reverse Seroconversion after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and the Impact of PostTransplant Vaccination

Sarah P. Hammond, Vincent T. Ho, Chinweike Ukomadu, Lindsey R. Baden, Francisco M. Marty

Parallel 29: HCV Virology

Monday, November 4

4:45 - 6:15 PM Room 151

MODERATORS: Stanley M. Lemon, MD

Raymond T. Chung, MD

4:45 PM

193: Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver

Stefan F Wieland, Zuzanna Makowska, Benedetta Campana, Diego Calabrese, Michael T. Dill, Josan Chung, Francis V. Chisari, Markus H. Heim

5:00 PM

194: Persistently Infected Hepatitis C Virus Cell Culture Impairs Type I But Not The Type III IFN Signaling

Partha K. Chandra, Kyoungsub Song, Darren P. Baker, Shuanghu Liu, Curt H. Hagedorn, Serge Y. Fuchs, Nathan J. Shores, Tong Wu, Luis A. Balart, Srikanta Dash

5:15 PM

195: Expression levels of IFNL4 and other IFN-λs are determined by dinucleotide polymorphism of IFNL4 and correlate with basal expression levels of interferon stimulated genes and effect of interferon

Hiromi Abe, C. Nelson Hayes, Nobuhiko Hiraga, Michio Imamura, Daiki Miki, Masataka Tsuge, Hidenori Ochi, Kazuaki Chayama

5:30 PM

196: Identification of Viral Double-stranded RNA as a Substrate for Hepatitis C Relapse and as a Target for Ribavirin

Arielle L. Klepper, Francis J. Eng, Adeeb Rahman, Brannon Weeks, Ahmed El-Shamy, M. Isabel Fiel, Gonzalo Carrasco, Sasan Roayaie, Meena Bansal, Thomas D. Schiano, Andrea D. Branch

5:45 PM

197: EFTUD2 regulates hepatitis C virus replication through the RIG-I/MDA5 pathway

Chuanlong Zhu, Jian Hong, Lei Zhao, Pattranuch Chusri, Nikolaus Jilg, Dahlene N. Fusco, Esperance A. Schaefer, Cynthia Brisac, Stephane Chevaliez, Daniel Wambua, Lee F. Peng, Wenyu Lin, Raymond T. Chung

6:00 PM

198: Impaired IFN signaling in chronic hepatitis C with advanced fibrosis via the TGF-β signaling pathway

Takayoshi Shirasaki, Masao Honda, Tetsuro Shimakami, Kazuhisa Murai, Takayuki Shiomoto, Hikari Okada, Riuta Takabatake, Stanley M. Lemon, Seishi Murakami, Shuichi Kaneko

Parallel 30: Innate Immunity in Hepatitis C Infection and Fibrosis

Monday, November 4

4:45 - 6:15 PM Room 146BC

MODERATORS: Barbara Rehermann, MD

Hugo R. Rosen, MD

4:45 PM

199: Global microRNA profiling reveals complex interactions among hepatic microRNA regulation, hepatitis C virus infection and interferon response

Hawwa F. Alao, Helen Cha, Stephan Chiu, Qisheng Li, T. Jake Liang

5:00 PM

200: HCV induces differentiation of CD14+ circulating monocytes via TLR8 into macrophage-like cells that exhibit M2 (alternative) polarization and profibrogenic effects

Banishree Saha, Gyongyi Szabo

5:15 PM

201: Monocytes Regulate NK Cell Antiviral Function in Hepatitis C via Inflammasome-Induced IL-18

Elisavet Serti, Jens M. Werner, Michael A. Chattergoon, Andrea Cox, Volker Lohmann, Barbara Rehermann

5:30 PM

202: Tissue macrophages are responsible for inflammatory liver disease in the hepatitis C virus transgenic mice

Kiminori Kimura, Takahiro Ohtsuki, Yuko Tokunaga, Michinori Kohara

5:45 PM

203: IL-4 Receptor alpha1 regulates M2 macrophage signaling and is an important modulator of liver fibrosis progression and regression

Shih-Yen Weng, Kornelius Padberg, Yong Ook Kim, Xiao-Yu Wang, Brombacher Frank, Detlef Schuppan

6:00 PM

204: Whole Genome Study to Characterize Potential Determinants of Aplastic Anemia in HCV Patients Receiving Combination Anti-viral Therapy

Jacob George, Alexander J. Thompson, Steven L. Flamm, Dongliang Ge, Matthew Paulson, Bittoo Kanwar, Phil S. Pang, Mani Subramanian, John G. McHutchison, David B. Goldstein, Lisa M. Nyberg, Thomas J. Urban

Parallel 31: Macrophages and Immunity in Alcoholic Liver Disease and Regeneration

Monday, November 4

4:45 - 6:15 PM Room 146A

MODERATORS: Philippe Mathurin, MD, PhD

Pranoti Mandrekar, PhD

4:45 PM

205: CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis

Matthias Bartneck, Josef Ehling, Xiao Wei, Viktor Fech, Christer Baeck, Kanishka Hittatiya, Tom Luedde, Fabian Kiessling, Twan Lammers, Christian Trautwein, Frank Tacke

5:00 PM

206: Alcoholic hepatitis not responding to medical therapy is related to a complex defect in liver regeneration

Laurent Dubuquoy, Alexandre Louvet, Guillaume Lassailly, Stephanie Truant, Emmanuel Boleslawski, David Buob, Florent Artru, Amelie Cannesson, Francois Maggiotto, Emilie Gantier, Christophe Moreno, Sebastien Dharancy, Philippe Mathurin

5:15 PM

207: γδ T cells promote liver regeneration via Dectin-1 dependent IL-17/IL-22 mediated inflammatory interplay

Raghavendra S. Rao, Christopher S. Graffeo, Rishabh Gulati, Suchithra Narayan, Tasnima Mohaimin, Stephanie Greco, Lena Tomkoetter, Eliza van Heerden, Rocky M. Barilla, Oscar Carazas, Reuven Blobstein, Yisroel Gelbstein, Atsuo Ochi, Constantinos P. Zambirinis, Michael Deutsch, George Miller

5:30 PM

208: Myeloid specific deficiency of gp96, a master chaperone of toll-like receptor 4 (TLR4), reduces inflammatory cytokines and protects against alcoholic liver injury

Aditya Ambade, Donna Catalano, Pranoti Mandrekar

5:45 PM

209: Alcohol-induced defects in transcytosis may be explained by decreased dynein processivity along hyperacetylated microtubules

Jennifer L. Groebner, David J. Fernandez, Dean J. Tuma, Pamela L. Tuma

6:00 PM

210: The role of neutrophil endotoxin tolerance in the predisposition to sepsis in alcohol-related liver disease

Jennifer M. Ryan, Godhev K. Manakkat Vijay, (Robin) Daniel Abeles, Thomas Tranah, Lee J. Markwick, Laura J. Blackmore, Antonio Riva, Nikhil Vergis, Nicholas J. Taylor, Shilpa Chokshi, Yun Ma, John G. O'Grady, Debbie Shawcross

SIG Program

Monday, November 4

4:45 - 6:45 PM Ballroom C

Selected Controversies in Adult and Pediatric NAFLD and NASH

Sponsored by the Pediatric Liver Disorders SIG and the Steatosis and Steatohepatitis SIG

MODERATORS: Mary E. Rinella, MD

Rohit Kohli, MD

NAFLD is the most prevalent liver disease in the developed world and a burgeoning epidemic in the developing world. Despite over a decade of intense investigations and major advances in our understanding of disease pathagenesis, we remain without established therapy. There are a myriad of controversies with respect to the management of NAFLD in both children and adults. As we learn more about proposed treatments for NAFLD and its associated conditions, controversy over their efficacy and true impact on the disease are again at the forefront as we manage this increasingly common condition.

Learning Objectives:

  • Discuss the role of vitamin E in the treatment of NASH in children and adults
  • Review the role of diet macronutrient content in the development and management of NAFLD
  • Understand the relationship between NAFLD and some of its comorbidities (e.g., cardiovascular disease, hypogonadism, growth hormone deficiency, dyslipidemia) in children and adults

4:45 - 4:50 PM Introduction

Mary E. Rinella, MD and Rohit Kohli, MD

Session I: Vitamin E in the Treatment of NASH

4:50 - 5:05 PM First Line Therapy or Waiting for Something Better?

Rohit Loomba, MD

5:05 - 5:20 PM Utility in Pediatrics

Joel E. Lavine, MD, PhD

5:20 - 5:28 PM Panel Discussion

Session II: Dietary Factors in Pathogenesis and Management of NASH

5:28 - 5:43 PM The Role of Macronutrients

Jacob George, MD, PhD

5:43 - 5:58 PM The Role of Fructose

Miriam B. Vos, MD

5:58 - 6:06 PM Panel Discussion

Session III: Co-morbidities of NAFLD: Innocent Bystanders or Independent Risk Factors?

6:06 - 6:21 PM Adult Perspective

Arun J. Sanyal, MD

6:21 - 6:36 PM Pediatric Perspective

Ariel E. Feldstein, MD

6:36 - 6:45 PM Panel Discussion

SIG Program

Monday, November 4

4:45 - 6:45 PM Room 152A

Cell Death in Hepatotoxicity

Sponsored by the Hepatotoxicity SIG

MODERATOR: Neil Kaplowitz, MD

Hepatotoxicity ultimately reflects a phenotype of hepatocyte death, irrespective of whether caused by drugs, toxins, or other agents acting through intrinsic stress mechanism within the hepatocyte or through extensile mechanisms involving the immune systems; this symposium will review current concepts and advances our understanding of hepatocytes death. This field has rapidy advanced over the past decade and continues to witness rapid progress.

Learning Objectives:

  • Review current understanding of cell death mechanisms which are the effectors of hepatotoxicity and their potential relevance to drug liver injury
  • Discuss controversies and identify areas of need of further advances
  • Identify new therapeutic targets to prevent or treat hepatotoxicity

4:45 - 4:50 PM Introduction

Neil Kaplowitz, MD

4:50 - 5:15 PM Update on Hepatocellular Apoptosis and Necrosis and New Therapeutic Targets

Christian Trautwein, MD

5:15 - 5:20 PM Discussion

5:20 - 5:45 PM Role of Mitochondrial Fission And Mitophagy In Cell Death

Xiao-Ming Yin, MD, PhD

5:45 - 5:55 PM Discussion

5:55 - 6:20 PM New Biomarkers of Apoptosis and Necrosis: Relevance To DILI

Ariel E. Feldstein, MD

6:20 - 6:45 PM Panel Discussion

Early Morning Workshops

Tuesday, November 5

6:45 - 7:45 AM Refer to your luncheon ticket for meeting room location.

Tuesday Basic Early Morning Workshops

EMW-29 Stellate Cell Biology

Rebecca G. Wells, MD and Natalie Torok, MD

EMW-30 HCV Immunology

Kyong-Mi Chang, MD and Markus H. Heim, MD

EMW-31 Liver Stem Cells

Holger Willenbring, MD, PhD and Wolfram Goessling, MD, PhD

EMW-32 Pathways for Hepatocarcinogenesis

Allan Tsung, MD and Josep M. Llovet, MD

EMW-33 Mechanisms of Alcoholic Liver Disease

Natalia Nieto, PhD and Hidekazu Tsukamoto, DVM, PhD

Tuesday Clinical Early Morning Workshops

EMW-34 Who Should Be Treated For Hepatitis C, Now And In The Future?

Andrew J. Muir, MD and Markus Peck-Radosavljevic, MD

EMW-35 Do We Have Enough New Drugs For Hepatitis C Yet?

David R. Nelson, MD and Jean-Michel Pawlotsky, MD, PhD

EMW-36 Barriers to Using New Antiviral Agents against Hepatitis C in Children

Maureen M. Jonas, MD and Philip Rosenthal, MD

EMW-37 Update on Hepatitis E

Kenneth E. Sherman, MD, PhD and Scott D. Holmberg, MD

EMW-38 Emerging Roles for Elastography in Chronic Liver Disease

Laurent Castera, MD, PhD and Massimo Pinzani, MD, PhD

EMW-39 Management of the Post-Kasai Patient

Ronald J. Sokol, MD and Richard A. Schreiber, MD

EMW-40 Ethical Considerations in Treating Liver Disease in Patients with Substance-Dependency

Adrian Reuben, MBBS, FRCP, FACG, Andrew Aronsohn, MD and Dirk J. van Leeuwen, MD, PhD

Poster Session IV

Tuesday, November 5

8:00 AM - Noon

Hall E

Refer to page 177A for Poster Presentations

Plenary Session

Presidential Plenary: Viral Hepatitis

Tuesday, November 5

8:00 - 9:30 AM Hall E/General Session

MODERATORS: Norah Terrault, MD

Adrian M. Di Bisceglie, MD

8:00 AM

211: All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial

Kazuaki Chayama, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Wenhua Hu, Hiroki Ishikawa, Eric A. Hughes, Hiromitsu Kumada

8:15 AM

212: All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1)

Mark S. Sulkowski, Maribel Rodriguez-Torres, Jacob P. Lalezari, W. Jeffrey Fessel, Karam Mounzer, Margaret C. Shuhart, Anne Luetkemeyer, David M. Asmuth, Anuj Gaggar, William T. Symonds, John G. McHutchison, Susanna Naggie, Douglas T. Dieterich

8:30 AM

213: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation

Michael P. Curry, Xavier Forns, Raymond T. Chung, Norah Terrault, Robert S. Brown, Jonathan M. Fenkel, Fredric D. Gordon, Jacqueline G. O'Leary, Alexander Kuo, Thomas D. Schiano, Gregory T. Everson, Eugene R. Schiff, Alex Befeler, John G. McHutchison, William T. Symonds, Jill M. Denning, Lindsay McNair, Sarah Arterburn, Dilip Moonka, Edward J. Gane, Nezam H. Afdhal

8:45 AM

214: Hepatitis A to E Virus Infections in Selected United States-bound Refugee Populations

Tonya Mixson-Hayden, Deborah Lee, Lilia Ganova-Raeva, Jan Drobeniuc, William Stauffer, Eyasu H. Teshale, Saleem Kamili

9:00 AM

215: Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in ≥95% Sustained Virologic Response In Patients with HCV Genotype 1, Including Patients with Cirrhosis: the LONESTAR trial

Eric Lawitz, Fred Poordad, Robert H. Hyland, Xiao Ding, Christy Hebner, Phil S. Pang, William T. Symonds, John G. McHutchison, Fernando E. Membreno

9:15 AM

216: Sustained Virological Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience

Audrey Coilly, Jerome Dumortier, Danielle Botta-Fridlund, Marianne Latournerie, Vincent Leroy, Georges-Philippe Pageaux, Emiliano G. Giostra, Christophe Moreno, Bruno Roche, Pascal Lebray, Sylvie Radenne, Anne-Catherine Saouli, Yvon Calmus, Laurent Alric, Maryline Debette-Gratien, Victor de Ledinghen, Francois Durand, Christophe Duvoux, Didier Samuel, Jean-Charles Duclos-Vallee

Hepatitis Debrief

Tuesday, November 5

9:30 - 10:30 AM Hall E/General Session

Hepatitis Debrief

Introduction by Howard K. Koh, MD, (invited)

Assistant Secretary for Health for the U.S. Department of Health and Human Services

SPEAKER: Mark S. Sulkowski, MD

This session will provide a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®. Attendees will leave this session with practical knowledge of cutting-edge therapies for chronic hepatitis C.

Leon Schiff State-of-the-Art Lecture

Tuesday, November 5

10:30 - 11:00 AM Hall E/General Session

HCV Therapeutics in the Post-Interferon Era: More than the Sum of its Parts?

SPEAKER: Robert T. Schooley, MD

MODERATOR: Adrian M. Di Bisceglie, MD

Learning Objectives:

  • Discuss the role of innate immune evasion mechanisms of HCV in establishing and maintaining chronic infection in the liver
  • Identify the potential implications of viral dynamics and replication fidelity as barriers to the pharmacologic cure of HCV infection
  • Describe mechanisms that may account for the better than expected results to date of directly acting agents in the treatment of infection

The Leon Schiff State-of-the-Art Lecture honors Dr. Schiff and recognizes the work he did to elevate the study and practice of hepatology to the discipline it is today. The restricted fund supporting this lecture ensures that future hepatologists will have a distinct platform from which to provide their valuable insights at The Liver Meeting®. AASLD gratefully acknowledges the National Genetics Institute for its generous support of this fund.

Parallel Session

Parallel 32: Alcohol Induced Mechanisms of Injury and Therapeutic Targets

Tuesday, November 5

11:15 AM -12:45 PM Room 145

MODERATORS: Hidekazu Tsukamoto, DVM, PhD

Min You, PhD

11:15 AM

217: Notch mediates macrophage M1 activation in ASH via metabolic reprograming

Jun Xu, Feng Chi, Samuel W. French, Hidekazu Tsukamoto

11:30 AM

218: Hepatocyte-derived metabolic danger signals, extracellular ATP and uric acid, synergistically induce inflammatory cell activation and represent therapeutic targets in alcoholic liver disease

Jan Petrasek, Arvin Iracheta-Vellve, Shashi Bala, Karen Kodys, Evelyn A. Kurt-Jones, Gyongyi Szabo

11:45 AM

219: The role of stem cell derived microvesicles and microRNAs during alcoholic liver injury

Phillip Levine, Kelly McDaniel, Shannon S. Glaser, Heather L. Francis, Yuyan Han, Julie Venter, Taylor Francis, Chang-Gong Liu, Hidekazu Tsukamoto, Gianfranco Alpini, Fanyin Meng

12:00 PM

220: Adipocyte-Specific Lipin-1 Deficiency Disturbs Adiponectin Signaling and Aggrevates Alcoholic Fatty Liver in Mice

Huquan Yin, Xiaomei Liang, Joanne M. Ajmo, Brian Finck, Min You

12:15 PM

221: Binge Drinking and Weight Gain Accentuate Eicosanoid Mediated Inflammation and Oxidative Injury in Alcoholic Liver Disease - Novel Pathophysiologic Insights from Lipidomic Analysis

Puneet Puri, Jun Xu, Faridoddin Mirshahi, Hae K Min, Tommy Pacana, Vaishali Patel, Kalyani Daita, Terhi Vihervaara, Riikka Katainen, Kim Ekroos, Andrew R. Joyce, Hidekazu Tsukamoto, Arun J. Sanyal

12:30 PM

222: Genetic Polymorphisms of Galectin-9 (Gal-9) Associated with Risk of Developing Alcoholic Liver Disease (ALD) in Humans

Hugo R. Rosen, Ann K. Daly, Lucy Golden-Mason, Christopher P. Day

Parallel 33: Experimental Cholestasis

Tuesday, November 5

11:15 AM -12:45 PM Room 152A

MODERATORS: Jorge A. Bezerra, MD

Cara Mack, MD

11:15 AM

223: SC-435, an Inhibitor of ASBT, Improves Liver Function in a Rat Partial Bile Duct Ligation Model of Cholestasis

Bradley T. Keller, Svetlana Nikoulina, Nicolaus Nazarenkov, Bronislava Gedulin

11:30 AM

224: Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids

Lirui Wang, Phillipp Hartmann, Michael Haimerl, Sai P. Bathena, Yazen Alnouti, Alan F. Hofmann, Bernd Schnabl

11:45 AM

225: NHERF-1 Knockout Mice Have Lower Hepatic ICAM-1 Expression and Are Protected from Liver Injury Induced by Bile Duct Ligation

Man Li, Albert Mennone, Carol J. Soroka, Kathy M. Harry, Edward J. Weinman, James L. Boyer

12:00 PM

226: Novel therapeutic implications of modulating β-Catenin during intrahepatic cholestasis

Kari Nejak-Bowen, Michael Thompson, Satdarshan (Paul) S. Monga

12:15 PM

227: Secretion of gonadotropin-releasing hormone (GnRH) by cholangiocytes stimulates biliary proliferation via autocrine/paracrine mechanisms

Debolina Ray, Sharon DeMorrow, Fanyin Meng, Julie Venter, Heather L. Francis, Laura Hargrove, Kelly McDaniel, Syeda H. Afroze, Paolo Onori, Eugenio Gaudio, Shannon S. Glaser, Gianfranco Alpini

12:30 PM

228: PPARα positively regulates human MDR3/ABCB4 transcription and increases biliary phosphatidylcholine secretion

Nisanne Ghonem, Meena Ananthanarayanan, Carol J. Soroka, James L. Boyer

Parallel 34: Experimental Hepatocarcinogenesis

Tuesday, November 5

11:15 AM -12:45 PM Room 146A

MODERATORS: Satdarshan (Paul) S. Monga, MD

Lopa Mishra, MD

11:15 AM

229: The Contribution of Toll-Like Receptor Signaling to the Development of Hepatic Fibrosis and Carcinogenesis in Hepatocyte Specific TAK1 Deleted Mice

Jingyi Song, Sayaka Inokuchi, Yoonseok Roh, Ling Yang, Ekihiro Seki

11:30 AM

230: High Mobility Group Box 1(HMGB1) Triggers Progenitor Expansion and Hepatocarcinogenesis in the Chronically Injured Liver

Peter Huebener, Pradere Jean-Philippe, Geum-Youn Gwak, Robert Schwabe

11:45 AM

231: Activated β-catenin and Yap Synergize to Promote Hepatoblastoma Formation in Mice

Satdarshan (Paul) S. Monga, Lili Zhou, Kari Nejak-Bowen, Sarangarajan Ranganathan, Junyan Tao, DIego Calvisi, Xin Chen

12:00 PM

232: Novel Genetic Model of Cholangiocarcinoma in Mice

Nataliya Razumilava, Daisaku Yamada, Steven Bronk, Jun Li, Jorge A. Bezerra, Xin Chen, Gregory J. Gores

12:15 PM

233: Genomics-based directions for targeted therapy in cholangiocarcinoma

Jesper B. Andersen, Valentina M. Factor, Snorri S. Thorgeirsson

12:30 PM

234: SYK(L) and its splicing variant SYK(S) exert opposing roles in hepatocellular carcinoma

Jian Hong, Yunfei Yuan, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Wenyu Lin, Jia Le Dai, Raymond T. Chung

Parallel 35: HCV Pathogenesis

Tuesday, November 5

11:15 AM -12:45 PM Ballroom C

MODERATORS: Jordan J. Feld, MD

Bruce R. Bacon, MD

11:15 AM

235: Macrophage Immunoregulatory Galectin-9 Production is increased by Contact with Hepatitis C Virus-infected Hepatocytes and Differentiation

Noah M. Harwood, Lucy Golden-Mason, Hugo R. Rosen, John A. Mengshol

11:30 AM

236: Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C atients with different interleukin 28B genotypes

Masao Honda, Takayoshi Shirasaki, Tetsuro Shimakami, Akito Sakai, Rika Horii, Kuniaki Arai, Tatsuya Yamashita, Yoshio Sakai, Taro Yamashita, Hikari Okada, Mikiko Nakamura, Eishiro Mizukoshi, Shuichi Kaneko

11:45 AM

237: Hepatic IFN lambda receptor 1 expression is induced in chronic hepatitis C and correlates with nonresponse to IFN alpha and IL28B minor alleles

Francois Duong, Gaia Trincucci, Tujana Boldanova, Sarah Durand, Mirjam B. Zeisel, Thomas F. Baumert, Markus H. Heim

12:00 PM

238: Intrahepatic Changes in the Endogenous Interferon Response are Associated with SVR in Chronic Hepatitis C, Genotype-1 Subjects Treated with Sofosbuvir and Ribavirin

Eric G. Meissner, Anu Osinusi, Honghui Wang, John G. McHutchison, William T. Symonds, Anthony F. Suffredini, Michael A. Polis, Henry Masur, Shyam Kottilil

12:15 PM

239: Validation study of the impact of SNPs from GWAS associated with fibrosis progression in chronic hepatitis

Lourdes Rojas, Javier Ampuero, Jose A. Del Campo, Jose Raul Garcfa-Lozano, Ricard Sola, Xavier Forns, Ricardo Moreno-Otero, Raul J. Andrade, Moises Diago, Javier Salmeron, Luis Rodrigo, Jose A Pons, J. M. Navarro, Jose L. Calleja, Javier García-Samaniego, Manuel Romero-Gomez

12:30 PM

240: The anti-HCV gene SART1 regulates IFN stimulated genes through nonclassical mechanisms

Wenyu Lin, Chuanlong Zhu, Jian Hong, Lei Zhao, Qikai Xu, Pattranuch Chusri, Nikolaus Jilg, Dahlene N. Fusco, Esperance A. Schaefer, Cynthia Brisac, Lee F. Peng, Raymond T. Chung

Parallel 36: Health Care Quality and Cost Effectiveness

Tuesday, November 5

11:15 AM -12:45 PM Room 150B


11:15 AM

241: Effect of Lead Time Bias in the Evaluation of the Effectiveness of a Screening Program: Example of Screening by Ultrasound for Hepatocellular Carcinoma (HCC) in Compensated HCV-Related Cirrhosis

Abbas Mourad, Michael Schwarzinger, Nathalie Ganne-Carrie, Isabelle Rosa, Philippe Mathurin, Sylvie Deuffic-Burban

11:30 AM

242: Non-invasive biomarkers unearth undiagnosed cirrhosis in the community

David J. Harman, Emilie A. Wilkes, Martin W. James, Stephen D. Ryder, Guruprasad P. Aithal, Indra Neil Guha

11:45 AM

243: The impact of Geography on organ allocation: Beyond the distance to the transplantation center

Rony Ghaoui, Jane Garb

12:00 PM

244: Real World Costs of Telaprevir-based Triple Therapy, Including Costs of Managing Adverse Events, at the Mount Sinai Medical Center, NY: $195,000 per SVR12

Kian Bichoupan, Valerie Martel-Laferriere, Michel Ng, Emily A. Schonfeld, Alexis Pappas, James F. Crismale, Alicia Stivala, Viktoriya Khaitova, Donald Gardenier, Ponni Perumalswami, Thomas D. Schiano, Joseph A. Odin, Lawrence U. Liu, Douglas T. Dieterich, Andrea D. Branch

12:15 PM

245: Cost-effectiveness of Hepatitis C Treatment by Primary Care Providers Supported by the Extension for Community Healthcare Outcomes (ECHO) Model

John B. Wong, Karla A. Thornton, Christie Carroll, Sanjeev Arora

12:30 PM

246: Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C Patients Receiving Care Through the U.S. Veterans Health Administration

Jeffrey McCombs, Tara Matsuda, Ivy Tonnu-Mihara, Sammy Saab, Patricia Hines, Gil L' Italian, Timothy Juday, Yong Yuan

Parallel 37: Liver Cancer: Pathogenesis and Treatment

Tuesday, November 5

11:15 AM -12:45 PM Ballroom AB

MODERATORS: Tamar H. Taddei, MD

Massimo Colombo, MD

11:15 AM

247: Continuation of metformin use after a diagnosis of cirrhosis significantly improved survival of patients with type II diabetes (DM)

Xiaodan Zhang, Teresa Mettler, William S. Harmsen, W. Ray Kim, Terry Therneau, Lewis R. Roberts, Roongruedee Chaiteerakij

11:30 AM

248: Metformin use improves survival of cholangiocarcinoma (CC) patients with type II diabetes (DM)

Roongruedee Chaiteerakij, Esha Baichoo, Lewis R. Roberts

11:45 AM

249: The Changing Characteristics of Hepatocellular Cancer Over Time

Linda L. Wong, Ma koto Ogihara, Naoky Tsai, Brenda Y. Hernandez, Herbert Yu

12:00 PM

250: A novel immunotherapeutic treatment for experimental hepatocellular carcinoma (HCC) using the host-defense derived peptide LTX-315

Pal Dag Line, Jihua Shi, Janne M. Nestvold, Meng Yu Wang, Gunnar Kvalheim, Øystein Rekdal

12:15 PM

251: Phase I Trial of Alpha-Fetoprotein-Derived Peptides in the Treatment of Hepatocellular Carcinoma

Eishiro Mizukoshi, Tatsuya Yamashita, Kuniaki Arai, Hajime Sunagozaka, Kazumi Fushimi, Hidetoshi Nakagawa, Kazutoshi Yamada, Kiichiro Kaji, Masaaki Kitahara, Shuichi Kaneko

12:30 PM

252: Impact of PNPLA3 (rs738409 C>G) variant in hepatocellular carcinoma: evidence from a metaanalysis

Eric Trepo, Pierre Nahon, Gianluca Bontempi, Luca Valenti, Edmondo Falleti, Hans Dieter Nischalke, Samia Hamza, Stefano Ginanni Corradini, Maria Antonella Burza, Erwan Guyot, Benedetta Donati, Ulrich Spengler, Patrick Hillon, Pierluigi Toniutto, Jean Henrion, Philippe Mathurin, Christophe Moreno, Stefano Romeo, Pierre Deltenre

Parallel 38: Signal Transduction and Nuclear Receptors

Tuesday, November 5

11:15 AM -12:45 PM Room 152B

MODERATORS: Mario Chojkier, MD

Mark J. Czaja, MD

11:15 AM

253: Retinoid acid related orphan receptor α (RORα) regulates circadian rhythm and fasting induction of sterol 12α-hydroxylase (CYP8B1) in bile acid synthesis

Preeti Pathak, Tiangang Li, John Chiang

11:30 AM

254: The novel function of small heterodimer partner (SHP) in integrating circadian rhythm and metabolism networks in the liver

Sangmin Lee, Yuxia Zhang, Hiroyuki Tsuchiya, Rana Smalling, Anton M. Jetten, Li Wang

11:45 AM

255: Cardiomyocyte specific deletion of bile acid membrane receptor-TGR5 induces contractile failure, exercise intolerance, inotropic insensitivity and alteration in cell signaling in mice

Moreshwar S. Desai, Zeena Eblimit, Corey Reynolds, Saul J. Karpen, David D. Moore, Daniel J. Penny

12:00 PM

256: The Hippo Tumor Suppressor Links Autophagy to Hepatic Growth Regulation

Youngmin A. Lee, Tingfang Lee, Luke A. Noon, Elisabeth G. Kramer, Gareth John, Cathie Pflefer, M. Isabel Fiel, Scrott L. Friedman

12:15 PM

257: Hypoxia-inducible factor 2alpha activation disrupts cholesterol metabolism homeostasis of liver and accelerates atherosclerosis in apoE-null mice

Aijuan Qu, Changtao Jiang, Fei Li, Naoki Tanaka, Bin Gao, Yatrik M. Shah, Frank J. Gonzalez

12:30 PM

258: FGF21 promotes cirrhosis associated angiogenesis through endocytosis dependent activation of FGFR1 in endothelial cells

Usman Yaqoob, Sheng Cao, Thiago de Assuncao, Vijay Shah

Parallel 39: Sterile Inflammation and Immunobiology

Tuesday, November 5

11:15 AM -12:45 PM Room 150A

MODERATORS: Wajahat Z. Mehal, MD

Robert Schwabe, MD

11:15 AM

259: NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis

Alexander Wree, Akiko Eguchi, Matthew D. McGeough, Casey Johnson, Carla A. Pena, Ali Canbay, Hal M. Hoffman, Ariel E. Feldstein

11:30 AM

260: An adenosine A2α receptor/HIF-1α axis Sustains Inflammasome Activation Resulting in Liver Injury and Fibrosis That Can Be Blocked by Digoxin

Xinshou Ouyang, Ayaz Ghani, Ahsan F. Malik, Bruce N. Cronstein, Wajahat Z. Mehal

11:45 AM

261: Intracellular HMGB1 in hepatocytes protects the liver from sterile inflammatory injury by mediating activation of Poly(ADP-ribose) polymerase-1 (PARP-1)

Hai Huang, Gary Nace, Sheng Tai, John R. Klune, Kerry-Ann Mcdonald, Allan Tsung

12:00 PM

262: C/EBP-beta Phosphorylation is Required for Liver Macrophage Inflammasome Activation and for the Induction of Liver Injury

Martina Buck, Mario Chojkier

12:15 PM

263: High Mobility Group Box 1(HMGB1) and its Receptor RAGE Promote Sterile Inflammation and Amplification of Acute Liver Injury

Peter Huebener, Pradere Jean-Philippe, Geum Youn Gwak, Robert Schwabe

12:30 PM

264: Hepatocyte-TNFRI Shedding Limits Excessive Inflammation during Sepsis via iNOS-cGMP-TACE-Dependent Signaling

Meihong Deng, Patricia Loughran, Melanie Scott, R. S. Chanthaphavong, Timothy R. Billiar